<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer - Chuai, Y - 2021 | Cochrane Library</title> <meta content="Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer - Chuai, Y - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013348.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer - Chuai, Y - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013348.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013348.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer" name="citation_title"/> <meta content="Yunhai Chuai&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Ivana Rizzuto&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Royal Brisbane and Women’s Hospital" name="citation_author_institution"/> <meta content="Xia Zhang&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="zx6055215@163.com" name="citation_author_email"/> <meta content="Ying Li" name="citation_author"/> <meta content="Guanghai Dai" name="citation_author"/> <meta content="Sophie J Otter" name="citation_author"/> <meta content="Royal Surrey County Hospital" name="citation_author_institution"/> <meta content="Rasiah Bharathan" name="citation_author"/> <meta content="University Hospitals of Leicester NHS Trust, Leicester General Hospital" name="citation_author_institution"/> <meta content="Alexandra Stewart" name="citation_author"/> <meta content="Royal Surrey County Hospital" name="citation_author_institution"/> <meta content="Aiming Wang" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD013348.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/03/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013348.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013348.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013348.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angiogenesis Inhibitors [adverse effects, *therapeutic use]; Antineoplastic Agents [adverse effects, *therapeutic use]; Bevacizumab [adverse effects, therapeutic use]; Bias; Brachytherapy [adverse effects]; Combined Modality Therapy [adverse effects, methods]; Confidence Intervals; Gastric Fistula [chemically induced]; Gastrointestinal Hemorrhage [chemically induced]; Hypertension [chemically induced]; Indazoles; Intestinal Fistula [chemically induced]; Intestinal Perforation [chemically induced]; Lapatinib [adverse effects, therapeutic use]; Neoplasm Recurrence, Local [blood supply, *drug therapy, mortality]; Progression-Free Survival; Pyridines [adverse effects, therapeutic use]; Pyrimidines [adverse effects, therapeutic use]; Quality of Life; Quinazolines [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Sulfonamides [adverse effects, therapeutic use]; Thromboembolism [chemically induced]; Uterine Cervical Neoplasms [blood supply, *drug therapy, mortality]; Vascular Endothelial Growth Factor A [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013348.pub2&amp;doi=10.1002/14651858.CD013348.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="UDgTyLGV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013348\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013348\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013348.pub2",title:"Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer",firstPublishedDate:"Mar 4, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013348.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013348.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013348.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013348.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013348.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013348.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013348.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013348.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013348.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013348.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5530 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013348.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-sec-0120"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-sec-0114"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/appendices#CD013348-sec-0125"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/table_n/CD013348StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/table_n/CD013348StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0004">Yunhai Chuai</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0005">Ivana Rizzuto</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Xia Zhang</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0007">Ying Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0008">Guanghai Dai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0009">Sophie J Otter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0010">Rasiah Bharathan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0011">Alexandra Stewart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information#CD013348-cr-0012">Aiming Wang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information/en#CD013348-sec-0133">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 March 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013348.pub2">https://doi.org/10.1002/14651858.CD013348.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013348-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013348-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013348-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013348-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013348-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013348-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013348-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013348-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013348-abs-0001" lang="en"> <section id="CD013348-sec-0001"> <h3 class="title" id="CD013348-sec-0001">Background</h3> <p>Cervical cancer ranks as the fourth leading cause of death from cancer in women. Historically, women with metastatic or recurrent cervical cancer have had limited treatment options. New anti‐angiogenesis therapies, such as vascular endothelial growth factor (VEGF) targeting agents, offer an alternative strategy to conventional chemotherapy; they act by inhibiting the growth of new blood vessels, thereby restricting tumour growth by blocking the blood supply. </p> </section> <section id="CD013348-sec-0002"> <h3 class="title" id="CD013348-sec-0002">Objectives</h3> <p>To assess the benefits and harms of VEGF targeting agents in the management of persistent, recurrent, or metastatic cervical cancer. </p> </section> <section id="CD013348-sec-0003"> <h3 class="title" id="CD013348-sec-0003">Search methods</h3> <p>We performed searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, online registers of clinical trials, and abstracts of scientific meetings up until 27 May 2020. </p> </section> <section id="CD013348-sec-0004"> <h3 class="title" id="CD013348-sec-0004">Selection criteria</h3> <p>We examined randomised controlled trials (RCTs) that evaluated the use of VEGF targeting agents alone or in combination with conventional chemotherapy or other VEGF targeting agents. </p> </section> <section id="CD013348-sec-0005"> <h3 class="title" id="CD013348-sec-0005">Data collection and analysis</h3> <p>Three review authors independently screened the results of search strategies, extracted data, assessed risk of bias, and analysed data according to the standard methods expected by Cochrane. The certainty of evidence was assessed via the GRADE approach. </p> </section> <section id="CD013348-sec-0006"> <h3 class="title" id="CD013348-sec-0006">Main results</h3> <p>A total of 1634 records were identified. From these, we identified four studies with a total of 808 participants for inclusion. We also identified two studies that were awaiting classification and nine ongoing studies. </p> <p><b>Bevacizumab plus chemotherapy versus chemotherapy</b> </p> <p>Treatment with bevacizumab plus chemotherapy may result in lower risk of death compared to chemotherapy alone (hazard ratio (HR) 0.77, 95% confidence interval (CI) 0.62 to 0.95; 1 study, 452 participants; low‐certainty evidence). However, there are probably more specific adverse events when compared to chemotherapy alone, including gastrointestinal perforations or fistulae (risk ratio (RR) 18.00, 95% CI 2.42 to 133.67; 1 study, 440 participants; moderate‐certainty evidence); serious thromboembolic events (RR 4.5, 95% CI 1.55 to 13.08; 1 study, 440 participants; moderate‐certainty evidence); and hypertension (RR 13.75, 95% CI 5.07 to 37.29; 1 study, 440 participants; moderate‐certainty evidence). There may also be a higher incidence of serious haemorrhage (RR 5.00, 95% CI 1.11 to 22.56; 1 study, 440 participants; low‐certainty evidence). In addition, the incidence of serious adverse events is probably higher (RR 1.44, 95% CI 1.16 to 1.79; 1 study, 439 participants; moderate‐certainty evidence). The incremental cost‐effectiveness ratio was USD 295,164 per quality‐adjusted life‐year (1 study, 452 participants; low‐certainty evidence). </p> <p><b>Cediranib plus chemotherapy versus chemotherapy</b> </p> <p>Treatment with cediranib plus chemotherapy may or may not result in similar risk of death when compared to chemotherapy alone (HR 0.94, 95% CI 0.53 to 1.65; 1 study, 69 participants; low‐certainty evidence). We found very uncertain results for the incidences of specific adverse events, including gastrointestinal perforations or fistulae (RR 3.27, 95% CI 0.14 to 77.57; 1 study, 67 participants; very low‐certainty evidence); serious haemorrhage (RR 5.45, 95% CI 0.27 to 109.49; 1 study, 67 participants; very low‐certainty evidence); serious thromboembolic events (RR 3.41, 95% CI 0.14 to 80.59; 1 study, 60 participants; very low‐certainty evidence); and serious hypertension (RR 0.36, 95% CI 0.02 to 8.62; 1 study, 67 participants; very low‐certainty evidence). In addition, there may or may not be a similar incidence of serious adverse events compared to chemotherapy alone (RR 1.15, 95% CI 0.75 to 1.78; 1 study, 67 participants; low‐certainty evidence). </p> <p><b>Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy</b> </p> <p>Treatment with apatinib plus chemotherapy or chemotherapy/brachytherapy may or may not result in similar risk of death compared to chemotherapy alone or chemotherapy/brachytherapy alone (HR 0.90, 95% CI 0.51 to 1.60; 1 study, 52 participants; low‐certainty evidence). However, hypertension events may occur at a higher incidence as compared to chemotherapy alone or chemotherapy/brachytherapy alone (RR 5.14, 95% CI 1.28 to 20.73; 1 study, 52 participants; low‐certainty evidence). </p> <p><b>Pazopanib plus lapatinib versus lapatinib</b> </p> <p>Treatment with pazopanib plus lapatinib may result in higher risk of death compared to lapatinib alone (HR 2.71, 95% CI 1.16 to 6.31; 1 study, 117 participants; low‐certainty evidence). We found very uncertain results for the incidences of specific adverse events, including gastrointestinal perforations or fistulae (RR 2.00, 95% CI 0.19 to 21.59; 1 study, 152 participants; very low‐certainty evidence); haemorrhage (RR 2.00, 95% CI 0.72 to 5.58; 1 study, 152 participants; very low‐certainty evidence); and thromboembolic events (RR 3.00, 95% CI 0.12 to 72.50; 1 study, 152 participants; very low‐certainty evidence). In addition, the incidence of hypertension events is probably higher (RR 12.00, 95% CI 2.94 to 49.01; 1 study, 152 participants; moderate‐certainty evidence). There may or may not be a similar incidence of serious adverse events as compared to lapatinib alone (RR 1.45, 95% CI 0.94 to 2.26; 1 study, 152 participants; low‐certainty evidence). </p> <p><b>Pazopanib versus lapatinib</b> </p> <p>Treatment with pazopanib may or may not result in similar risk of death as compared to lapatinib (HR 0.96, 95% CI 0.67 to 1.38; 1 study, 152 participants; low‐certainty evidence). We found very uncertain results for the incidences of specific adverse events, including gastrointestinal perforations or fistulae (RR 1.03, 95% CI 0.07 to 16.12; 1 study, 150 participants; very low‐certainty evidence); haemorrhage (RR 1.03, 95% CI 0.31 to 3.40; 1 study, 150 participants; very low‐certainty evidence); and thromboembolic events (RR 3.08, 95% CI 0.13 to 74.42; 1 study, 150 participants; very low‐certainty evidence). In addition, the incidence of hypertension events is probably higher (RR 11.81, 95% CI 2.89 to 48.33; 1 study, 150 participants; moderate‐certainty evidence). The risk of serious adverse events may or may not be similar as compared to lapatinib (RR 1.31, 95% CI 0.83 to 2.07; 1 study, 150 participants; low‐certainty evidence). </p> </section> <section id="CD013348-sec-0007"> <h3 class="title" id="CD013348-sec-0007">Authors' conclusions</h3> <p>We found low‐certainty evidence in favour of the use of bevacizumab plus chemotherapy. However, bevacizumab probably increases specific adverse events (gastrointestinal perforations or fistulae, thromboembolic events, hypertension) and serious adverse events. We found low‐certainty evidence that does not support the use of cediranib plus chemotherapy, apatinib plus chemotherapy, apatinib plus chemotherapy/brachytherapy, or pazopanib monotherapy. We found low‐certainty evidence suggesting that pazopanib plus lapatinib worsens outcomes. The VEGF inhibitors apatinib and pazopanib may increase the probability of hypertension events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013348-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013348-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013348-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013348-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013348-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013348-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013348-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013348-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013348-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013348-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013348-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013348-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013348-abs-0002" lang="en"> <h3>Inhibition of blood vessel formation in advanced cervical cancer</h3> <p><b>What is the aim of this review?</b><br/>The aim of this Cochrane Review is to find out whether vascular endothelial growth factor (VEGF) targeting drugs, which inhibit the formation of new blood vessels, can improve survival in women with cervical cancer that has spread to distant sites (metastasised) or has not responded to or come back (recurred) after initial treatment. These drugs include bevacizumab, cediranib, apatinib, pazopanib, anlotinib, and nintedanib. </p> <p><b>Key messages</b><br/>Bevacizumab plus chemotherapy may improve survival and probably increases specific and serious adverse events, including gastrointestinal perforations through the gut wall, blood clot formation (thromboembolic events) in blood vessels, hypertension (increased blood pressure), and bleeding (haemorrhage). </p> <p>Cediranib or apatinib plus chemotherapy, or pazopanib alone, may make little to no difference in survival. Pazopanib plus lapatinib may reduce survival. </p> <p><b>What are the main results of the review?</b><br/>We found four randomised controlled trials (RCTs) that met our inclusion criteria and enrolled 808 women. </p> <p>We found one study, which included 452 women, that assessed the use of bevacizumab plus chemotherapy versus chemotherapy alone. The inclusion of bevacizumab may improve overall survival and probably increases the incidences of specific and serious adverse events. </p> <p>A second study analysed 69 women treated with cediranib plus chemotherapy versus chemotherapy alone. Cediranib may make little to no difference in survival, and it is uncertain whether it increases the incidences of specific or serious adverse events. </p> <p>Another study with 59 women reported data on the use of apatinib plus chemotherapy or chemoradiotherapy (concurrent chemotherapy and radiotherapy) versus chemotherapy or chemoradiotherapy alone. Apatinib may make little to no difference in survival, but it exhibited promising efficacy for progression‐free survival. </p> <p>We found one study with 228 women that compared pazopanib plus lapatinib versus only lapatinib, or pazopanib versus lapatinib: pazopanib plus lapatinib may reduce survival and probably increases the incidence of hypertension; pazopanib alone may make little to no difference in survival and probably increases the incidence of hypertension. </p> <p>Overall the quality (certainty) of the evidence was low, as each comparison included only one study and most studies were small. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013348-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013348-sec-0120"></div> <h3 class="title" id="CD013348-sec-0121">Implications for practice</h3> <section id="CD013348-sec-0121"> <p>Low‐certainty evidence suggests that the use of bevacizumab plus chemotherapy for women with persistent, recurrent, or metastatic cervical cancer prolonged median overall survival (OS) by 3.5 months as compared to chemotherapy alone. This benefit showed some heterogeneity and appeared to be greater in previously untreated women with pelvic disease, with cancers of the squamous histological type, and at medium/high risk by the Moore criteria (<a href="./references#CD013348-bbs2-0090" title="MooreDH , TianC , MonkBJ , LongHJ , OmuraGA , BlossJD . Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecologic Oncology2010;116(1):44-9.">Moore 2010</a>). Meanwhile, women should weigh any potential benefit versus increased serious and specific adverse events and should determine whether they would be able to afford the incremental costs. </p> <p>Low‐certainty evidence does not support the use of cediranib plus chemotherapy, as it did not improve OS as compared to chemotherapy alone. The effects of other tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor (VEGF) receptor (apatinib, anlotinib, nintedanib) plus chemotherapy are being assessed in ongoing studies. </p> <p>Low‐certainty evidence does not support the use of apatinib plus chemotherapy or chemotherapy/brachytherapy, as this treatment did not improve OS as compared to chemotherapy or chemotherapy/ brachytherapy alone. </p> <p>Low‐certainty evidence does not support the use of pazopanib plus lapatinib, which reduced OS as compared to lapatinib monotherapy. </p> <p>Low‐certainty certainty evidence does not support the use of pazopanib monotherapy, as it did not improve OS as compared to lapatinib monotherapy. </p> <p>No certain conclusions can be drawn as yet from <a href="./references#CD013348-bbs1-0004" title="">Ongoing studies</a> looking at apatinib plus anti‐programmed death 1 antibody plus chemoradiotherapy, or apatinib monotherapy versus supportive care. </p> </section> <h3 class="title" id="CD013348-sec-0122">Implications for research</h3> <section id="CD013348-sec-0122"> <p>Persistent, recurrent, or metastatic cervical cancer is a heterogeneous disease with different patient or disease factors. Future studies should assess the drug responses of specific subgroups and should search for predictive biomarkers of response to VEGF targeting agents. </p> <p>Most participants included in clinical trials discontinued treatment due to disease progression or toxicity. These women needed additional salvage therapy or supportive care until death. Future studies should assess the effects of subsequent line treatments on OS for these women and should fully evaluate quality of life outcomes for this group when treatment is largely provided with palliative intent. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013348-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013348-sec-0008"></div> <div class="table" id="CD013348-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bevacizumab plus chemotherapy compared to chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bevacizumab plus chemotherapy compared to chemotherapy for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with persistent, recurrent, or metastatic cervical cancer </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> bevacizumab plus chemotherapy </p> <p><b>Comparison:</b> chemotherapy only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with the chemotherapy only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with bevacizumab plus chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>791 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>701 per 1000<br/>(621 to 774) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.77<br/>(0.62 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>452<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum follow‐up was longer than 50 months. Median overall survival in the bevacizumab groups was 16.8 months (mortality rate 170/227 participants). Median overall survival in the control groups was 13.3 months (mortality rate 178/225 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific</b> <b>adverse events: gastrointestinal perforations or fistulae</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1,000<br/>(11 to 608) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 18.00<br/>(2.42 to 133.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>440<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 18 women (a maximum of 23) had fistulae events (N = 18) or perforation events (N = 5) in the bevacizumab group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious haemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1,000<br/>(10 to 205) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.00<br/>(1.11 to 22.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>440<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious thromboembolic events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1,000<br/>(28 to 238) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.50<br/>(1.55 to 13.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>440<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: hypertension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1,000<br/>(92 to 678) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 13.75<br/>(5.07 to 37.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>440<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>361 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>519 per 1,000<br/>(418 to 646) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.44<br/>(1.16 to 1.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Economic evaluation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>452<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incremental cost‐effectiveness ratio (ICER) was USD 295,164 per quality‐adjusted life‐year (QALY), or USD 24,597 per quality‐adjusted life‐month </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious heterogeneity. Outcomes might be different in different subgroups in the only included study. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by one for serious risk of bias. This analysis was not planned in the study protocol. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013348-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cediranib plus chemotherapy compared to placebo plus chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cediranib plus chemotherapy compared to placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with persistent, recurrent, or metastatic cervical cancer </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> cediranib plus chemotherapy </p> <p><b>Comparison:</b> placebo plus chemotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo plus chemotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cediranib plus chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>771 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000<br/>(543 to 912) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.94<br/>(0.53 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median follow‐up was 24.2 months. Median overall survival in the cediranib group was 13.6 months (mortality rate 25/34 participants). Median overall survival in the placebo group was 14.8 months (mortality rate 27/35 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: gastrointestinal perforations or fistulae</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.27<br/>(0.14 to 77.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious haemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.45<br/>(0.27 to 109.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious thromboembolic events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.41<br/>(0.14 to 80.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious</b> <b>hypertension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 246) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.36<br/>(0.02 to 8.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>514 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>591 per 1000<br/>(386 to 915) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.15<br/>(0.75 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic evaluation ‐ not measured</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious heterogeneity. Outcomes might be different in different subgroups in the only included study. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by two for very serious imprecision. There were few events and the confidence interval included appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013348-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Apatinib plus chemotherapy or chemotherapy/brachytherapy compared to chemotherapy or chemotherapy/brachytherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Apatinib plus chemotherapy or chemotherapy/brachytherapy compared with chemotherapy or chemotherapy/brachytherapy for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with recurrent or FIGO stage IVB cervical cancer </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> apatinib plus chemotherapy or chemotherapy/brachytherapy </p> <p><b>Comparison:</b> chemotherapy or chemotherapy/brachytherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with <b>chemotherapy or chemotherapy/brachytherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with a<b>patinib</b> <b>plus chemotherapy or chemotherapy/brachytherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000<br/>(161 to 429) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.90<br/>(0.51 to 1.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median follow‐up was 14 months. Median overall survival in the apatinib group was 14.7 months (mortality rate 11/28 participants). Median overall survival in the control group was 12.8 months (mortality rate 16/24 participants) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: haemorrhage ‐ not reported</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: thromboembolic events ‐ not reported</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: hypertension</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>428 per 1000<br/>(107 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.14<br/>(1.28 to 20.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events ‐ not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic evaluation ‐ not measured</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; FIGO: International Federation of Obstetrics and Gynaecology; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious risk of bias. This single small study was funded by the drug manufacturer. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by one for serious risk of bias. Trial registration occurred later than trial completion. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013348-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pazopanib plus lapatinib compared to lapatinib</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pazopanib plus lapatinib compared to lapatinib for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with persistent, recurrent, or metastatic cervical cancer </p> <p><b>Setting:</b> clinic </p> <p><b>Intervention:</b> pazopanib plus lapatinib </p> <p><b>Comparison:</b> lapatinib only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lapatinib only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with pazopanib plus lapatinib</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401 per 1000<br/>(197 to 697) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 2.71<br/>(1.16 to 6.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum follow‐up was longer than 40 weeks. Median overall survival in the pazopanib plus lapatinib group was 25.7 weeks (mortality rate 14/59 participants). Median overall survival in the lapatinib group was 35.0 weeks (mortality rate 10/58 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: gastrointestinal perforations or fistulae</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/>(3 to 284) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00<br/>(0.19 to 21.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: haemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1000<br/>(47 to 367) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00<br/>(0.72 to 5.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 10 women (maximum of 29) with 29 bleeding events were included in the pazopanib plus lapatinib group; at least 5 women (maximum of 11) with 11 bleeding events were included in the lapatinib group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: thromboembolic events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00<br/>(0.12 to 72.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: hypertension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>316 per 1000<br/>(77 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 12.00<br/>(2.94 to 49.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>289 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>420 per 1000<br/>(272 to 654) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.45<br/>(0.94 to 2.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A total of 5 women In the pazopanib plus lapatinib group had fatal adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic evaluation ‐ not measured</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious risk of bias. This single small study was funded by the drug manufacturer. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by two for very serious imprecision. There were few events and the confidence interval included appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013348-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pazopanib compared to lapatinib</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pazopanib compared to lapatinib for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with persistent, recurrent, or metastatic cervical cancer </p> <p><b>Setting:</b> clinic </p> <p><b>Intervention:</b> pazopanib only </p> <p><b>Comparison:</b> lapatinib only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lapatinib only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with pazopanib only</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>795 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>781 per 1000<br/>(654 to 888) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.96<br/>(0.67 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum follow‐up was longer than 150 weeks. Median overall survival in the pazopanib group was 49.7 weeks (mortality rate 56/74 participants). Median overall survival in the lapatinib group was 44.1 weeks (mortality rate 62/78 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: gastrointestinal perforations or fistulae</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(1 to 212) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.07 to 16.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: haemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(20 to 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.31 to 3.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 5 women (maximum of 13) in the pazopanib group had 13 bleeding events; at least 5 women (maximum of 11) in the lapatinib group had 11 bleeding events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: thromboembolic events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.08<br/>(0.13 to 74.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: hypertension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/>(76 to 1,000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 11.81<br/>(2.89 to 48.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>289 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>379 per 1000<br/>(240 to 599) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.31<br/>(0.83 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic evaluation ‐ not measured</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious risk of bias. This single small study was funded by the drug manufacturer. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by two for very serious imprecision. There were few events and the confidence interval included appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013348-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013348-sec-0009"></div> <section id="CD013348-sec-0010"> <h3 class="title" id="CD013348-sec-0010">Description of the condition</h3> <p>Cervical cancer is the second most commonly diagnosed cancer affecting women worldwide and the third leading cause of death from cancer among women in low‐income countries (<a href="./references#CD013348-bbs2-0033" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>; <a href="./references#CD013348-bbs2-0052" title="FerlayJ , ColombetM , SoerjomataramI , MathersC , ParkinDM , PinerosM , et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer2019;144:1941-53.">Ferlay 2019</a>; <a href="./references#CD013348-bbs2-0108" title="SiegelRL , MillerKD , JemalA . Cancer statistics, 2019. CA: A Cancer Journal for Clinicians2019;69:7-34.">Siegel 2019</a>). Almost 70% of the global burden falls on low‐ and middle‐income countries, in which 9 out of 10 cervical cancer deaths occur (<a href="./references#CD013348-bbs2-0052" title="FerlayJ , ColombetM , SoerjomataramI , MathersC , ParkinDM , PinerosM , et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer2019;144:1941-53.">Ferlay 2019</a>). A woman's risk of developing cervical cancer before the age of 74 years is estimated to be 1.36% worldwide, ranging from 0.9% in more developed to 1.6% in less developed areas (<a href="./references#CD013348-bbs2-0052" title="FerlayJ , ColombetM , SoerjomataramI , MathersC , ParkinDM , PinerosM , et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer2019;144:1941-53.">Ferlay 2019</a>; <a href="./references#CD013348-bbs2-0118" title="TorreLA , BrayF , SiegelRL , FerlayJ , Lortet-TieulentJ , JemalA . Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians2015;65:87-108.">Torre 2015</a>). The World Health Organization (WHO) recognises three pathological types of cervical cancer, including squamous cell carcinoma (70% to 80%), adenocarcinoma (20% to 25%), and other types (adenosquamous carcinoma, neuroendocrine tumour, and undifferentiated carcinoma) (<a href="./references#CD013348-bbs2-0081" title="MarthC , LandoniF , MahnerS , McCormackM , Gonzalez-MartinA , ColomboN . Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2017;28(Suppl 4):iv72-iv83.">Marth 2017</a>). Since the introduction of cytology‐based cervical screening, the incidence and mortality rates of cervical cancer have been reduced by approximately 75% in countries with co‐ordinated population vaccination and screening programmes (<a href="./references#CD013348-bbs2-0035" title=" Cancer Research UK . Incidence of cervical cancer. www.cruk.org.uk.">Cancer Research UK 2014</a>; <a href="./references#CD013348-bbs2-0068" title="ISD Scotland. Cancer incidence. www.idsscotland.org/health-topics/cancer/publications/index.asp (accessed July 2014).">ISD Scotland 2011</a>; <a href="./references#CD013348-bbs2-0108" title="SiegelRL , MillerKD , JemalA . Cancer statistics, 2019. CA: A Cancer Journal for Clinicians2019;69:7-34.">Siegel 2019</a>; <a href="./references#CD013348-bbs2-0124" title="Welsh Cancer Intelligence and Surveillance Unit. Cancer incidence 2001-2017. www.wcisu.wales.nhs.uk.">Welsh Cancer Intelligence and Surveillance 2011</a>). A majority of cervical cancer cases (60%) are associated with inadequate screening and therefore are potentially preventable, or cervical cancer may be diagnosed at a very early stage, remaining easily curable with surgery (<a href="./references#CD013348-bbs2-0024" title="AlldredgeJK , TewariKS . Clinical trials of antiangiogenesis therapy in recurrent/persistent and metastatic cervical cancer. Oncologist2016;21(5):576-85.">Alldredge 2016</a>; <a href="./references#CD013348-bbs2-0049" title="EskanderRN , TewariKS . Targeting angiogenesis in advanced cervical cancer. Therapeutic Advances in Medical Oncology2014;6(6):280-92.">Eskander 2014</a>; <a href="./references#CD013348-bbs2-0099" title="ReboljM , RimmerJ , DentonK , TidyJ , MathewsC , EllisK , et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ2019;364:1-10.">Rebolj 2019</a>). However, even in women diagnosed at a relatively early stage who have undergone treatment with surgery or radical chemoradiotherapy, the risk of recurrence is 10% to 20% for stages IB to IIA, and 28% to 64% for locally advanced FIGO stages IIB to IV, as per the classification of the International Federation of Obstetrics and Gynaecology (FIGO) (see <a href="#CD013348-fig-0001">Figure 1</a> for FIGO cervical cancer staging 2018) (<a href="./references#CD013348-bbs2-0028" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>; <a href="./references#CD013348-bbs2-0029" title="BhatlaN , BerekJS , CuelloFM , DennyLA , GrenmanS , KarunaratneK , et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology &amp; Obstetrics2019;145(1):129-35.">Bhatla 2019</a>; <a href="./references#CD013348-bbs2-0033" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>; <a href="./references#CD013348-bbs2-0035" title=" Cancer Research UK . Incidence of cervical cancer. www.cruk.org.uk.">Cancer Research UK 2014</a>). </p> <div class="figure" id="CD013348-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="FIGO stage 2018 (with correction Bhatla 2018; Bhatla 2019)." data-id="CD013348-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>FIGO stage 2018 (with correction <a href="./references#CD013348-bbs2-0028" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>; <a href="./references#CD013348-bbs2-0029" title="BhatlaN , BerekJS , CuelloFM , DennyLA , GrenmanS , KarunaratneK , et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology &amp; Obstetrics2019;145(1):129-35.">Bhatla 2019</a>). </p> </div> </div> </div> <p>Early‐stage cancer (FIGO stages IA, IB1, IB2, and IIA1) can be treated by surgery or chemoradiotherapy (<a href="./references#CD013348-bbs2-0028" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>; <a href="./references#CD013348-bbs2-0029" title="BhatlaN , BerekJS , CuelloFM , DennyLA , GrenmanS , KarunaratneK , et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology &amp; Obstetrics2019;145(1):129-35.">Bhatla 2019</a>; <a href="./references#CD013348-bbs2-0081" title="MarthC , LandoniF , MahnerS , McCormackM , Gonzalez-MartinA , ColomboN . Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2017;28(Suppl 4):iv72-iv83.">Marth 2017</a>; <a href="./references#CD013348-bbs2-0094" title="NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. www.nccn.org/professionals/physician_gls/default.aspx#site (accessed prior to 16 May 2019).">NCCN 2018</a>). For locally advanced disease (FIGO stages IB3 to IVA), standard treatment is concurrent platinum‐based chemoradiotherapy, such as weekly cisplatin, during radiotherapy (<a href="./references#CD013348-bbs2-0028" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>; <a href="./references#CD013348-bbs2-0029" title="BhatlaN , BerekJS , CuelloFM , DennyLA , GrenmanS , KarunaratneK , et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology &amp; Obstetrics2019;145(1):129-35.">Bhatla 2019</a>; <a href="./references#CD013348-bbs2-0081" title="MarthC , LandoniF , MahnerS , McCormackM , Gonzalez-MartinA , ColomboN . Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2017;28(Suppl 4):iv72-iv83.">Marth 2017</a>; <a href="./references#CD013348-bbs2-0094" title="NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. www.nccn.org/professionals/physician_gls/default.aspx#site (accessed prior to 16 May 2019).">NCCN 2018</a>). In general, five‐year survival rates are 99% for stage IA1 and 98% for stage IA2; for stages IB to IIA, five‐year survival rates are 88% to 95% without lymph node metastasis, and 51% to 78% with lymph node metastasis; for stage IIB, the rate is 65%, for stage III 40%, and for stage IV 10% to 20% (<a href="./references#CD013348-bbs2-0037" title="CaoZ . Chinese Obstetrics and Gynecology. 3rd edition. Beijing: People's Medical Publishing House, 2014.">Cao 2014</a>; <a href="./references#CD013348-bbs2-0073" title="KimSM , ChoiHS , ByunJS . Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. International Journal of Gynecological Cancer2000;10(4):305-12.">Kim 2000</a>). Very advanced cervical cancer (FIGO stage IVB), in which the disease has spread to areas outside of the pelvis upon diagnosis (distant metastatic disease), has a very poor prognosis. Treatment options are limited and are unlikely to be curative; therefore management is aimed at prolonging life and managing symptoms. Similarly, in recurrent disease, unless exenterative surgery is possible, women usually are treated with palliative chemotherapy. Chemotherapy aims to prolong survival, provide symptom control, and improve quality of life. For women not medically fit enough for chemotherapy, treatment options in both metastatic and recurrent disease may be limited to at best supportive care, with the option of palliative radiotherapy, if appropriate (<a href="./references#CD013348-bbs2-0047" title="ElejeGU , EkeAC , IgberaseGO , IgwegbeAO , ElejeLI . Palliative interventions for controlling vaginal bleeding in advanced cervical cancer (Review). Cochrane Database of Systematic Reviews2019;3:1-30. [CD011000]">Eleje 2019</a>; <a href="./references#CD013348-bbs2-0051" title="FanfaniF , VizzaE , LandoniF , deIacoP , FerrandinaG , CorradoG , et al. Radical hysterectomy after chemoradiation in FIGO stage III cervical cancer patients versus chemoradiation and brachytherapy: complications and 3 years survival. European Journal of Surgical Oncology2016;24:Epub ahead of print.">Fanfani 2016</a>; <a href="./references#CD013348-bbs2-0058" title="GreerB , KohW , Abu-RustumN , ApteS , CamposS , ChanJ , et al. Cervical cancer. Journal of the National Cancer Institute2010;8:1388-416.">Greer 2010</a>; <a href="./references#CD013348-bbs2-0082" title="MatsuoK , MabuchiS , OkazawaM , KawanoM , KurodaH , KamiuraS , et al. Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors. Journal of Gynecologic Oncology2015;26(1):3-11.">Matsuo 2015</a>; <a href="./references#CD013348-bbs2-0120" title="WaggonerSE . Cervical cancer. Lancet2003;361:2217-25.">Waggoner 2003</a>). </p> <p>Persistent, recurrent, and metastatic diseases are the main causes of death among women with cervical cancer (<a href="./references#CD013348-bbs2-0103" title="ScatchardK , ForrestJL , FlubacherM , CornesP , WilliamsC . Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD006469. [DOI: 10.1002/14651858.CD006469.pub2]">Scatchard 2012</a>). In persistent disease, visible lesions appear within six months of primary surgery, or within three to six months of completion of primary radiotherapy; in recurrent disease, visible lesions appear within an interval of more than six months after primary surgery, or within three to six months of completion of primary chemoradiotherapy (<a href="./references#CD013348-bbs2-0036" title="CaoZ . China Gynaecological Oncology. 1st edition. Beijing: People's Military Surgeon Publishing House, 2011.">Cao 2011</a>). More than 60% of recurrent diseases are detected within two years of primary treatment, and about 10% are detected after five years (<a href="./references#CD013348-bbs2-0036" title="CaoZ . China Gynaecological Oncology. 1st edition. Beijing: People's Military Surgeon Publishing House, 2011.">Cao 2011</a>). Persistent or recurrent cancers occur in about 35% of women with stages IB to IIA disease, and in 50% to 70% of patients with stages IIB to IVa disease; if cancer recurs, five‐year survival rates drop to 5% to 10% (<a href="./references#CD013348-bbs2-0025" title="ArbynM , WeiderpassE , BruniL , deSanjoséS , SaraiyaM , FerlayJ , et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health2020;8(2):e191-203.">Arbyn 2020</a>; <a href="./references#CD013348-bbs2-0038" title="CaoZ . Cervical Carcinoma. 1st edition. Beijing: People's Medical Publishing House, 2017.">Cao 2017</a>; <a href="./references#CD013348-bbs2-0039" title="CaoW , YaoX , CenD , ZhiY , ZhuN , XuL . Prognostic role of pretreatment thrombocytosis on survival in patients with cervical cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology2019;17(132):1-10.">Cao 2019</a>). More than 60% of recurrent disease occurs in the pelvic cavity, including the central pelvic cavity (uterine cervix, vagina, and uterine body), parametrium, and pelvic side wall (<a href="./references#CD013348-bbs2-0037" title="CaoZ . Chinese Obstetrics and Gynecology. 3rd edition. Beijing: People's Medical Publishing House, 2014.">Cao 2014</a>). Women who experience distant metastases (i.e. cancer that has spread from the original (primary) tumour location to distant organs or distant lymph nodes, outside of the pelvis), either upon initial diagnosis (FIGO stage IVB) or at the time of recurrence, will have a poor prognosis. In recurrent disease, metastatic rates (16% to 31% for IB and IIA, 26% for IIB, 39% for III, and 75% for IVA) increase with FIGO stage (<a href="./references#CD013348-bbs2-0038" title="CaoZ . Cervical Carcinoma. 1st edition. Beijing: People's Medical Publishing House, 2017.">Cao 2017</a>). Sites of distant metastatic disease often include the lungs (21%), bone (16%), the para‐aortic region (11%), the abdominal cavity (8%), and the supraclavicular region (7%) (<a href="./references#CD013348-bbs2-0037" title="CaoZ . Chinese Obstetrics and Gynecology. 3rd edition. Beijing: People's Medical Publishing House, 2014.">Cao 2014</a>). Three phase 3 randomised trials (GOG‐204, GOG‐240, and Japanese Clinical Oncology Group 0505 (JCOG‐0505)) have examined chemotherapy regimens for women with advanced and recurrent cervical cancer (<a href="./references#CD013348-bbs2-0086" title="MonkBJ , SillMW , BurgerRA , GrayHJ , BuekersTE , RomanLD . Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology2009;27(7):1069-74.">Monk 2009a</a>; <a href="./references#CD013348-bbs2-0102" title="SaitoI , KitagawaR , FukudaH , ShibataT , KatsumataN , KonishiI , et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Japanese Journal of Clinical Oncology2010;40(1):90-3.">Saito 2010</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>). The main concern was acquired resistance to platinum‐based chemotherapy in individuals with recurrent cervical cancer who were previously treated with chemotherapy. However, regimens that did not include a platinum agent were not found to be superior to cisplatin‐based treatments; therefore cisplatin plus paclitaxel remains the chemotherapy standard for recurrent and metastatic disease (<a href="./references#CD013348-bbs2-0047" title="ElejeGU , EkeAC , IgberaseGO , IgwegbeAO , ElejeLI . Palliative interventions for controlling vaginal bleeding in advanced cervical cancer (Review). Cochrane Database of Systematic Reviews2019;3:1-30. [CD011000]">Eleje 2019</a>; <a href="./references#CD013348-bbs2-0088" title="MonkBJ . Evidence-based therapy for recurrent cervical cancer. Journal of Clinical Oncology2014;32(25):2687-90.">Monk 2014</a>). </p> <p>Angiogenesis inhibitors are a class of promising biological agents that target the process by which a tumour forms new blood vessels to supply it with oxygen and nutrients. This process is key to the growth of cervical cancer, both locally and in metastatic deposits (<a href="./references#CD013348-bbs2-0125" title="WillmottLJ , MonkBJ . Cervical cancer therapy: current, future and anti-angiogenesis targeted treatment. Expert Review of Anticancer Therapy2009;9(7):895-903.">Willmott 2009</a>). In 1971, Folkman proposed a tumour angiogenesis‐dependent doctrine, which suggested that the development of tumours was due to the ability of individual cancer cells to grow without normal controls but was also dependent on the nutrient and oxygen supply via blood vessels (<a href="./references#CD013348-bbs2-0053" title="FolkmanJ . Tumor angiogenesis: therapeutic implications. New England Journal of Medicine1971;285:1182-6.">Folkman 1971</a>). The transition of a tumour from an avascular to a vascular phase was termed the 'angiogenic switch' and was thought to be an important factor in the clinical progression from tumour dormancy to cancerous invasion (<a href="./references#CD013348-bbs2-0063" title="HanahanD , FolkmanJ . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell1996;86(3):353-64.">Hanahan 1996</a>). The angiogenic switch occurs through a dynamic process involving pro‐angiogenic and anti‐angiogenic factors that are normally maintained in balance (physiological homeostasis). Cancer is characterised by up‐regulation of pro‐angiogenic factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet‐derived growth factor (PDGF), and angiopoietins, and down‐regulation of anti‐angiogenic factors, such as thrombospondin, angiostatin, and endostatin, leading to the development of new blood vessels (neovascularisation) and tumour progression (<a href="./references#CD013348-bbs2-0064" title="HicklinDJ , EllisLM . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology2005;23:1011-27.">Hicklin 2005</a>). Neovascularisation is therefore a vital process in metastatic spread, which allows malignant cells to enter into the circulation (<a href="./references#CD013348-bbs2-0050" title="FalzoneL , SalomoneS , LibraM . Evolution of cancer pharmacological treatments at the turn of the third millennium. Frontiers in Pharmacology2018;9:1-26.">Falzone 2019</a>; <a href="./references#CD013348-bbs2-0053" title="FolkmanJ . Tumor angiogenesis: therapeutic implications. New England Journal of Medicine1971;285:1182-6.">Folkman 1971</a>; <a href="./references#CD013348-bbs2-0054" title="FolkmanJ . What is the evidence that tumors are angiogenesis dependent?Journal of the National Cancer Institute1990;82:4-6.">Folkman 1990</a>; <a href="./references#CD013348-bbs2-0097" title="PfaendlerKS , TewariKS . Changing paradigms in the systemic treatment of advanced cervical cancer. Expert Reviews Gynecology2016;214(1):23-8.">Pfaendler 2016</a>). Activation of VEGF promotes the proliferation and migration of endothelial cells, which form the lining of blood vessels, and the development of new blood vessels. Moreover, VEGF activation enhances the leakiness (permeability) of existing blood vessels and consequently causes increased leakage of multiple plasma proteins that are involved in the angiogenesis process (<a href="./references#CD013348-bbs2-0093" title="NagyJA , DvorakAM , DvorakHF . VEGF-A and the induction of pathological angiogenesis. Annual Review of Pathology2007;2:251-75.">Nagy 2007</a>; <a href="./references#CD013348-bbs2-0119" title="TurajlicS , SwantonC , BoshoffC . Kidney cancer: the next decade. Journal of Experimental Medicine2018;215(10):2477-9.">Turajlic 2018</a>). These proteins are ligands to three VEGF receptors (VEGF‐R1 to ‐R3) and are responsible for initiating a cascade of reactions that promote the migration, proliferation, and survival of endothelial cells, leading to the formation of new blood vessels. VEGF‐R1 and VEGF‐R2 are responsible for the regulation of angiogenesis, whereas VEGF‐R3 plays a secondary role in angiogenesis but is essential for lymphangiogenesis (development of new lymphatic vessels) and therefore is involved in the production of ascites and lymphatic dissemination of metastatic factors (<a href="./references#CD013348-bbs2-0048" title="EllisLM , HicklinDJ . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews. Cancer2008;8:579-91.">Ellis 2008</a>). Angiogenesis is present in pre‐malignant conditions of the cervix, as well as in invasive disease, which can be seen at colposcopy with the occurrence of vascular changes. Studies have shown that microvessel (small vessel) density increases progressively with the grades of cervical intraepithelial neoplasia (CIN), suggesting that angiogenesis may be an early event in the development of cervical pre‐cancer and cancer (<a href="./references#CD013348-bbs2-0046" title="DobbsSP , HewettPW , JohnsonIR , CarmichaelJ , MurrayJC . Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. British Journal of Cancer1997;76(11):1410-5.">Dobbs 1997</a>; <a href="./references#CD013348-bbs2-0061" title="GuidiAJ , FischerL , HarrisJR , SchmittSJ . Microvessel density and distribution in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute1994;86:614-9.">Guidi 1994</a>; <a href="./references#CD013348-bbs2-0075" title="KrillLS , TewariKS . Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer. Clinical Therapeutics2015;37(1):9-19.">Krill 2015</a>; <a href="./references#CD013348-bbs2-0109" title="Smith-McCuneKK , WeidnerN . Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Research1994;54:800-4.">Smith‐McCune 1994</a>). Cervical cancer has been shown to be more dependent on angiogenesis than most other solid cancers because human papillomavirus (the cause of almost all cervical cancers) and hypoxia, with increased hypoxia‐inducible factor 1 alpha, are associated with higher levels of VEGF (<a href="./references#CD013348-bbs2-0087" title="MonkBJ , SillMW , McMekinS , CohnDE , RamodettaLM , BoardmanCH , et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynaecological Oncology Group study. Journal of Clinical Oncology2009;27(28):4649-55.">Monk 2009b</a>). In addition, increased intratumoural microvessel density during histological examination and enhanced expression of proteins, such as the endothelial antigen CD31, have been associated with a poor prognosis (<a href="./references#CD013348-bbs2-0044" title="DellasA , MochH , SchultheissE , FeichterG , AlmendralA , GudatF , et al. Association of tumour induced vascularization with clinicopathological parameters in cervical neoplasm. International Journal of Oncology1997;11(1):105-9.">Dellas 1997</a>; <a href="./references#CD013348-bbs2-0046" title="DobbsSP , HewettPW , JohnsonIR , CarmichaelJ , MurrayJC . Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. British Journal of Cancer1997;76(11):1410-5.">Dobbs 1997</a>; <a href="./references#CD013348-bbs2-0116" title="TjalmaW , SonnemansH , WeylerJ , Van MarckE , Van DaeleA , Van DamP . Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence. American Journal of Obstetrics and Gynecology1999;181(3):554-9.">Tjalma 1999</a>). Targeting the cancer microenvironment, specifically, new blood vessel formation, using VEGF pathway inhibition is the main goal of inhibition of angiogenesis. </p> </section> <section id="CD013348-sec-0011"> <h3 class="title" id="CD013348-sec-0011">Description of the intervention</h3> <p>Angiogenesis, the development of new blood vessels, is essential for initiation of tumours, their growth, and metastasis (<a href="./references#CD013348-bbs2-0112" title="TanA , XiaN , GaoF , MoZ , CaoY . Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007958. [DOI: 10.1002/14651858.CD007958.pub2]">Tan 2010</a>). Tumours require angiogenesis to receive enough nutrients and oxygen to grow beyond 1 to 2 mm in diameter and to facilitate metastasis (<a href="./references#CD013348-bbs2-0121" title="WagnerAD , ArnoldD , GrotheyAAG , HaertingJ , UnverzagtS . Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD005392. [DOI: 10.1002/14651858.CD005392.pub3]">Wagner 2009</a>). The process of tumour‐related angiogenesis is regulated by various pro‐angiogenic factors, such as VEGF, and their cognate receptors, which are the dominant regulators of the proliferation of endothelial cells and the formation of new blood vessels (<a href="./references#CD013348-bbs2-0112" title="TanA , XiaN , GaoF , MoZ , CaoY . Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007958. [DOI: 10.1002/14651858.CD007958.pub2]">Tan 2010</a>). VEGF acts by binding to its receptor, which then signals within the cell via tyrosine kinase enzyme activity (tyrosine kinases). VEGF‐R1 (Flt‐1 or fms‐like‐tyrosine kinase) and VEGF‐R2 (KDR/flk‐1) belong to the best characterised angiogenesis signalling pathway, and they can be blocked by inhibitors, such as antibodies (bevacizumab) or soluble receptors, which bind to VEGF and prevent it from binding to its receptors on cells. VEGF‐R2 is thought to be the dominant receptor responsible for translating and regulating angiogenesis (<a href="./references#CD013348-bbs2-0026" title="BelloneS , FreraG , LandolfiG , RomaniC , BandieraE , TognonG , et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology2007;106:513-20.">Bellone 2007</a>). </p> <p>Unlike chemotherapy agents that attack tumour cells, angiogenesis inhibitors are developed to block VEGF signalling pathways (<a href="./references#CD013348-bbs2-0069" title="JaysonGC , KerbelR , EllisLM , HarrisAL . Antiangiogenic therapy in oncology: current status and future directions. Lancet2016;388(10043):518-29.">Jayson 2016</a>). This was first shown in 1993, when anti‐VEGF monoclonal antibodies were found to exert a potent inhibitory effect on the growth of three tumour cell lines injected subcutaneously into mice (<a href="./references#CD013348-bbs2-0072" title="KimKJ , LiB , WinerJ , ArmaniniM , GillettN , PhillipsHS , et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature1993;29(362):6423.">Kim 1993</a>). It is interesting to note that the antibody had no effects on cell lines in vitro. However, several parallel studies confirmed in vivo growth inhibition, which correlated with decreased tumour microvessel density and inhibition of tumour angiogenesis (<a href="./references#CD013348-bbs2-0030" title="BorgstromP , HillanK , SriramaraoP , FerraraN . Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Research1996;56:4032-9.">Borgstrom 1996</a>; <a href="./references#CD013348-bbs2-0031" title="BorgstromP , BourdonM , HillanK , SriramaraoP , FerraraN . Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumours in vivo. Prostate1998;35:1-10.">Borgstrom 1998</a>; <a href="./references#CD013348-bbs2-0032" title="BorgstromP , GoldD , HillanK , FerraraN . Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Research1999;19:4203-14.">Borgstrom 1999</a>). It is now known that VEGF targeting agents ‐ angiogenesis inhibitors ‐ starve the tumour by preventing the formation of blood vessels and inhibit the growth and spread of tumours. VEGF targeting agents have been tested in some solid tumours, including metastatic colorectal cancer, metastatic thyroid cancer, ovarian cancer, high‐grade glioblastoma, and endocrine refractory or resistant metastatic breast cancer (<a href="./references#CD013348-bbs2-0056" title="GaitskellK , MartinekI , BryantA , KehoeS , NicumS , MorrisonJ . Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD007930. [DOI: 10.1002/14651858.CD007930.pub2]">Gaitskell 2011</a>; <a href="./references#CD013348-bbs2-0071" title="KhasrawM , AmeratungaMS , GrantR , WheelerH , PavlakisN . Antiangiogenic therapy for high-grade glioma. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD008218. [DOI: 10.1002/14651858.CD008218.pub3]">Khasraw 2014</a>; <a href="./references#CD013348-bbs2-0112" title="TanA , XiaN , GaoF , MoZ , CaoY . Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007958. [DOI: 10.1002/14651858.CD007958.pub2]">Tan 2010</a>; <a href="./references#CD013348-bbs2-0121" title="WagnerAD , ArnoldD , GrotheyAAG , HaertingJ , UnverzagtS . Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD005392. [DOI: 10.1002/14651858.CD005392.pub3]">Wagner 2009</a>; <a href="./references#CD013348-bbs2-0122" title="WagnerAD , ThomssenC , HaertingJ , UnverzagtS . Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD008941. [DOI: 10.1002/14651858.CD008941.pub2]">Wagner 2012</a>). </p> <p>Phase 1 to 3 clinical trials of some VEGF targeting agents (bevacizumab, cediranib, pazopanib, sunitinib, and sorafenib) have been completed in women with persistent, recurrent, metastatic, and locally advanced cervical cancer (<a href="./references#CD013348-bbs2-0080" title="MackayHJ , TinkerA , WinquistE , ThomasG , SwenertonK , OzaA , et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND 184. Gynecologic Oncology2010;116(2):163-7.">Mackay 2010</a>; <a href="./references#CD013348-bbs2-0084" title="MilosevicMF , TownsleyCA , ChaudaryN , ClarkeB , PintilieM , FanS , et al. Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a Phase 1 clinical study. International Journal of Radiation Oncology Biology Physics2016;94(1):111-7.">Milosevic 2016</a>; <a href="./references#CD013348-bbs2-0086" title="MonkBJ , SillMW , BurgerRA , GrayHJ , BuekersTE , RomanLD . Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology2009;27(7):1069-74.">Monk 2009a</a>; <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>; <a href="./references#CD013348-bbs2-0105" title="SchefterT , WinterK , KwonJS , StuhrK , BalarajK , YaremkoBP , et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. International Journal of Radiation Oncology Biology Physics2014;88(1):101-5.">Schefter 2014</a>; <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>; <a href="./references#CD013348-bbs2-0128" title="ZighelboimI , WrightJD , GaoF , CaseAS , MassadLS , MutchDG . Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecologic Oncology2013;130(1):64-8.">Zighelboim 2013</a>). Bevacizumab is a humanised monoclonal antibody directed against all major isoforms of VEGF (VEGF‐A, VEGF‐B, VEGF‐C, VEGF‐D, placental growth factor (PIGF), VEGF‐E, and VEGF‐F members). It is used extensively in the USA and is the most studied biological agent in gynaecological cancer (<a href="./references#CD013348-bbs2-0060" title="GrotheyA , GalanisE . Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature Reviews. Clinical Oncology2009;6:507-18.">Grothey 2009</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>). Several published randomised controlled trials (RCTs) and non‐randomised trials have reported binding and inactivation of VEGF through the clinical use of bevacizumab as a single agent (<a href="./references#CD013348-bbs2-0086" title="MonkBJ , SillMW , BurgerRA , GrayHJ , BuekersTE , RomanLD . Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology2009;27(7):1069-74.">Monk 2009a</a>; <a href="./references#CD013348-bbs2-0087" title="MonkBJ , SillMW , McMekinS , CohnDE , RamodettaLM , BoardmanCH , et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynaecological Oncology Group study. Journal of Clinical Oncology2009;27(28):4649-55.">Monk 2009b</a>; <a href="./references#CD013348-bbs2-0104" title="SchefterT , WinterK , KwonJ , StuhrK , BalarajK , YaremkoB , et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. International Journal of Radiation Oncology, Biology, Physics2012;83:1179-84.">Schefter 2012</a>; <a href="./references#CD013348-bbs2-0105" title="SchefterT , WinterK , KwonJS , StuhrK , BalarajK , YaremkoBP , et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. International Journal of Radiation Oncology Biology Physics2014;88(1):101-5.">Schefter 2014</a>; <a href="./references#CD013348-bbs2-0110" title="TakanoM , IkedaY , KudohK , KitaT , SasakiN , KikuchiY . Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin. Journal of Obstetrics and Gynaecology2013;39(4):872-5.">Takano 2013</a>; <a href="./references#CD013348-bbs2-0112" title="TanA , XiaN , GaoF , MoZ , CaoY . Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007958. [DOI: 10.1002/14651858.CD007958.pub2]">Tan 2010</a>; <a href="./references#CD013348-bbs2-0113" title="TewariKS , MonkBJ . Gynaecological group trials of chemotherapy for metastatic and recurrent cervical cancer. Current Oncology Reports2005;7(6):419-34.">Tewari 2005</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>; <a href="./references#CD013348-bbs2-0114" title="TewariKS , MonkBJ . New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Clinical Cancer Research2014;20(21):5349-58.">Tewari 2014b</a>; <a href="./references#CD013348-bbs2-0126" title="WrightJ , VivianoD , PowellM , GibbR , MutchD , GrigsbyP , et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecologic Oncology2006;103:489-93.">Wright 2006</a>). It has now been approved in more than 60 countries for the treatment of persistent, recurrent, or metastatic disease, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan, based on improved overall survival (OS) with typical adverse events (hypertension, thromboembolic events, and gastrointestinal fistulae) in the Gynecologic Oncology Group (GOG)‐240 trial (<a href="./references#CD013348-bbs2-0115" title="TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al, Gynecologic Oncology Group 240. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial. Lancet2017;390(10103):1654-63.">Tewari 2017</a>). </p> <p>The treatment plan for persistent, recurrent, or metastatic cervical cancer depends on the performance status of the person with cancer (i.e. his or her general well‐being), the disease site, the extent of disease, and previous treatment (<a href="./references#CD013348-bbs2-0028" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>; <a href="./references#CD013348-bbs2-0029" title="BhatlaN , BerekJS , CuelloFM , DennyLA , GrenmanS , KarunaratneK , et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology &amp; Obstetrics2019;145(1):129-35.">Bhatla 2019</a>). For women with isolated distant metastasis or locoregional recurrence (i.e. original microscopic cancer cells that have resisted primary therapy and become visible at the original site), treatment includes individualised radiotherapy (external radiation or brachytherapy (intracavity radiotherapy), or both), with or without cisplatin chemotherapy; surgical resection can be used for control of local disease and symptoms (<a href="./references#CD013348-bbs2-0094" title="NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. www.nccn.org/professionals/physician_gls/default.aspx#site (accessed prior to 16 May 2019).">NCCN 2018</a>). For women with central pelvic recurrence after primary radiotherapy, pelvic exenteration (i.e. removal of part or all of the pelvic organs), with or without intraoperative radiotherapy, may be considered. Surgical mortality rates of less than 5% and long‐term survival rates of approximately 50% have been reported (<a href="./references#CD013348-bbs2-0091" title="MorleyGW , HopkinsMP , LindenauerSM , RobertsJA . Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstetrics and Gynecology1989;74(6):934-43.">Morley 1989</a>). Radical hysterectomy or brachytherapy may also be considered, if the central pelvic lesion is small (&lt; 2 cm) and isolated (<a href="./references#CD013348-bbs2-0094" title="NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. www.nccn.org/professionals/physician_gls/default.aspx#site (accessed prior to 16 May 2019).">NCCN 2018</a>). For women with extrapelvic metastases or recurrences who are unsuitable to undergo surgery or radiotherapy, combination cisplatin‐based chemotherapy regimens are often recommended (i.e. paclitaxel and cisplatin combined with bevacizumab) over the use of single agents (<a href="./references#CD013348-bbs2-0094" title="NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. www.nccn.org/professionals/physician_gls/default.aspx#site (accessed prior to 16 May 2019).">NCCN 2018</a>). However, overall response rates to chemotherapy are about 20% (15% to 46%), with median OS of six to eight months and median progression‐free survival (PFS) of three months (<a href="./references#CD013348-bbs2-0081" title="MarthC , LandoniF , MahnerS , McCormackM , Gonzalez-MartinA , ColomboN . Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2017;28(Suppl 4):iv72-iv83.">Marth 2017</a>; <a href="./references#CD013348-bbs2-0089" title="MooreDH . Chemotherapy for recurrent cervical carcinoma. Current Opinions in Oncology2006;18(5):516-9.">Moore 2006</a>; <a href="./references#CD013348-bbs2-0113" title="TewariKS , MonkBJ . Gynaecological group trials of chemotherapy for metastatic and recurrent cervical cancer. Current Oncology Reports2005;7(6):419-34.">Tewari 2005</a>). </p> </section> <section id="CD013348-sec-0012"> <h3 class="title" id="CD013348-sec-0012">How the intervention might work</h3> <p>Over‐expression of VEGF has been found in most human cancers compared with normal tissues (<a href="./references#CD013348-bbs2-0069" title="JaysonGC , KerbelR , EllisLM , HarrisAL . Antiangiogenic therapy in oncology: current status and future directions. Lancet2016;388(10043):518-29.">Jayson 2016</a>). VEGF is released by tumour cells and interacts with its receptor (VEGF‐R), a transmembrane protein, on the nearby endothelial cells of normal blood vessels (see <a href="./references#CD013348-bbs2-0056" title="GaitskellK , MartinekI , BryantA , KehoeS , NicumS , MorrisonJ . Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD007930. [DOI: 10.1002/14651858.CD007930.pub2]">Gaitskell 2011</a> for figures describing receptor function). VEGF binds to the extracellular domain of VEGF‐R, stimulates tyrosine kinase activity in the intracellular domain of VEGF‐R, and triggers the downstream network of cell signalling pathways that promote the proliferation of endothelial cells and the formation of new blood vessels (<a href="./references#CD013348-bbs2-0070" title="KerbelRS . Tumor angiogenesis. New England Journal of Medicine2008;358(19):2039-49.">Kerbel 2008</a>). VEGF and VEGF‐R have already become the dominant targets for clinical angiogenesis inhibitors (<a href="./references#CD013348-bbs2-0069" title="JaysonGC , KerbelR , EllisLM , HarrisAL . Antiangiogenic therapy in oncology: current status and future directions. Lancet2016;388(10043):518-29.">Jayson 2016</a>). VEGF signalling pathways can be blocked by several mechanisms, including VEGF blockades (e.g. anti‐VEGF antibodies (bevacizumab), VEGF‐trap (aflibercept)), VEGF‐R blockades (e.g. anti‐VEGF‐R antibodies (ramucirumab)), and interruption of intracellular signalling pathways (e.g. tyrosine kinase inhibitors (TKIs) cediranib, pazopanib, sorafenib, sunitinib) (<a href="./references#CD013348-bbs2-0024" title="AlldredgeJK , TewariKS . Clinical trials of antiangiogenesis therapy in recurrent/persistent and metastatic cervical cancer. Oncologist2016;21(5):576-85.">Alldredge 2016</a>). Results of xenograft models of human tumours in mice have shown that VEGF targeting agents cause regression of microvascular tissues and reduction in metastatic disease progression (<a href="./references#CD013348-bbs2-0057" title="Genentech, Inc. Full prescribing information: Avastin (bevacizumab) injection for intravenous use. Available from https://www.gene.com/download/pdf/avastin_prescribing.pdf (accessed 9 November 2020).">Genentech 2020</a>; <a href="./references#CD013348-bbs2-0092" title="MortonCL , MarisJM , KeirST , GorlickR , KolbEA , BillupsCA , et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatric Blood and Cancer2012;58(4):566-71.">Morton 2012</a>). </p> <p>Bevacizumab (Avastin) is a VEGF‐directed antibody that has been given as an intravenous infusion as monotherapy or with other therapies to treat cervical cancer in clinical trials. In a phase 2 study of 46 women with persistent or recurrent squamous cell carcinoma, single‐agent bevacizumab was active and well tolerated. Median OS was 7.29 months, and median PFS was 3.40 months, with common severe adverse events of hypertension, thromboembolic events, and gastrointestinal disorders (<a href="./references#CD013348-bbs2-0086" title="MonkBJ , SillMW , BurgerRA , GrayHJ , BuekersTE , RomanLD . Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology2009;27(7):1069-74.">Monk 2009a</a>). In a phase 2 study of 27 women with persistent or recurrent disease (66.6% were squamous), bevacizumab was used with cisplatin and topotecan, median OS was 13.2 months, and median PFS was 7.1 months. However, severe haematologic toxicities were common, including thrombocytopenia, leukopenia, anaemia, and neutropenia. Most of the women required at least one unexpected hospital admission for supportive care (<a href="./references#CD013348-bbs2-0128" title="ZighelboimI , WrightJD , GaoF , CaseAS , MassadLS , MutchDG . Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecologic Oncology2013;130(1):64-8.">Zighelboim 2013</a>). In a phase 2 study of 49 women with locally advanced disease (63% were IIB, 80% were squamous), bevacizumab (10 mg/kg every 14 days for three cycles) was used with concurrent platinum‐based chemoradiotherapy; three‐year OS and PFS rates were 81.3% and 68.7%, respectively, and no significant treatment‐related adverse events occurred (<a href="./references#CD013348-bbs2-0105" title="SchefterT , WinterK , KwonJS , StuhrK , BalarajK , YaremkoBP , et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. International Journal of Radiation Oncology Biology Physics2014;88(1):101-5.">Schefter 2014</a>). In a GOG‐240 phase 3 study of 452 women with persistent, recurrent, or metastatic cervical cancer (68.6% were squamous), participants were randomised to receive bevacizumab with chemotherapy (paclitaxel and cisplatin, or paclitaxel and topotecan) or chemotherapy alone. The addition of bevacizumab to chemotherapy improved median OS to 17.0 months versus 13.3 months, and median PFS to 8.2 months versus 5.9 months, compared with chemotherapy alone. However, adverse events, including hypertension, severe thromboembolic events, and severe gastrointestinal fistulae, were increased (<a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>). </p> <p>Cediranib (Recentin) is a small molecule TKI of VEGF‐R. In a phase 2 study of 69 women with metastatic or recurrent disease, participants were randomised to receive cediranib with chemotherapy (paclitaxel and carboplatin) or chemotherapy alone. The addition of cediranib to chemotherapy improved median PFS as compared with chemotherapy alone (8.1 months versus 6.7 months) but did not improve median OS (13.6 months versus 14.8 months); adverse events, including hypertension, febrile neutropenia, and diarrhoea, were increased (<a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>). </p> <p>Pazopanib (Votrient) is an oral multi‐targeted TKI of VEGF‐R, a platelet‐derived growth factor receptor (PDGF‐R), and c‐kit. Lapatinib is an oral dual TKI of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu). In a phase 2 study of 228 women with persistent, recurrent, or metastatic cervical cancer, participants were randomised to receive single‐agent pazopanib (800 mg once daily), single‐agent lapatinib (1500 mg once daily), or pazopanib plus lapatinib (this arm was terminated due to toxicity). Pazopanib improved median OS (50.7 weeks versus 39.1 weeks) and PFS (18.1 weeks versus 17.1 weeks) as compared with lapatinib; the most common adverse events were similar in both groups: diarrhoea, nausea, hypertension, and anorexia (<a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>). </p> <p>Sunitinib (Sutent) is an oral multi‐targeted TKI of VEGF‐R, PDGF‐R, and c‐kit. In a phase 2 study of 19 women with incurable locally advanced or metastatic disease, single‐agent sunitinib was administered in a six‐week cycle for up to a maximum of six cycles; no tumour response was observed during follow‐up (median 4.4 months), and five cases of fistula formation were observed (<a href="./references#CD013348-bbs2-0080" title="MackayHJ , TinkerA , WinquistE , ThomasG , SwenertonK , OzaA , et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND 184. Gynecologic Oncology2010;116(2):163-7.">Mackay 2010</a>). </p> <p>Sorafenib (Nexavar) is an oral multi‐targeted inhibitor that targets both VEGF‐R and PDGF‐R tyrosine kinase and Raf serine/threonine kinase. In a phase 1 study of 13 women with locally advanced disease, sunitinib was administered before and during concurrent platinum‐based chemoradiotherapy, but the study was terminated after a preliminary analysis because sorafenib increased tumour hypoxia, which is a strong predictor of disease progression (<a href="./references#CD013348-bbs2-0084" title="MilosevicMF , TownsleyCA , ChaudaryN , ClarkeB , PintilieM , FanS , et al. Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a Phase 1 clinical study. International Journal of Radiation Oncology Biology Physics2016;94(1):111-7.">Milosevic 2016</a>). </p> </section> <section id="CD013348-sec-0013"> <h3 class="title" id="CD013348-sec-0013">Why it is important to do this review</h3> <p>Increasing knowledge about the molecular biology of gynaecological cancers has led to the development of biological therapies. Treatment options for persistent, recurrent, and metastatic cervical cancer are limited, and the purpose of current treatment is to relieve symptoms and improve quality of life (<a href="./references#CD013348-bbs2-0028" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>; <a href="./references#CD013348-bbs2-0081" title="MarthC , LandoniF , MahnerS , McCormackM , Gonzalez-MartinA , ColomboN . Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2017;28(Suppl 4):iv72-iv83.">Marth 2017</a>; <a href="./references#CD013348-bbs2-0094" title="NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. www.nccn.org/professionals/physician_gls/default.aspx#site (accessed prior to 16 May 2019).">NCCN 2018</a>). Other agents have not shown a survival advantage compared with standard therapy (<a href="./references#CD013348-bbs2-0081" title="MarthC , LandoniF , MahnerS , McCormackM , Gonzalez-MartinA , ColomboN . Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2017;28(Suppl 4):iv72-iv83.">Marth 2017</a>; <a href="./references#CD013348-bbs2-0094" title="NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. www.nccn.org/professionals/physician_gls/default.aspx#site (accessed prior to 16 May 2019).">NCCN 2018</a>). However, a phase 3 clinical trial showed that the addition of bevacizumab to chemotherapy improved survival from 13.3 months to 16.8 months (<a href="./references#CD013348-bbs2-0096" title="PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , LongHJ , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: an NGR Oncology/Gynecologic Oncology Group Study. Lancet Oncology2015;16(3):301-11.">Penson 2015</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>; <a href="./references#CD013348-bbs2-0115" title="TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al, Gynecologic Oncology Group 240. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial. Lancet2017;390(10103):1654-63.">Tewari 2017</a>). Since publication of the early results of <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, bevacizumab has become the standard of care in combination with chemotherapy for individuals with metastatic and recurrent cervical cancer in some high‐income countries (<a href="./references#CD013348-bbs2-0057" title="Genentech, Inc. Full prescribing information: Avastin (bevacizumab) injection for intravenous use. Available from https://www.gene.com/download/pdf/avastin_prescribing.pdf (accessed 9 November 2020).">Genentech 2020</a>). Other anti‐angiogenic agents have been studied to a lesser degree than bevacizumab. </p> <p>Cochrane Reviews of VEGF targeting therapy have been produced for glioma and for thyroid, ovarian, colorectal, and breast cancers (<a href="./references#CD013348-bbs2-0056" title="GaitskellK , MartinekI , BryantA , KehoeS , NicumS , MorrisonJ . Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD007930. [DOI: 10.1002/14651858.CD007930.pub2]">Gaitskell 2011</a>; <a href="./references#CD013348-bbs2-0071" title="KhasrawM , AmeratungaMS , GrantR , WheelerH , PavlakisN . Antiangiogenic therapy for high-grade glioma. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD008218. [DOI: 10.1002/14651858.CD008218.pub3]">Khasraw 2014</a>; <a href="./references#CD013348-bbs2-0112" title="TanA , XiaN , GaoF , MoZ , CaoY . Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007958. [DOI: 10.1002/14651858.CD007958.pub2]">Tan 2010</a>; <a href="./references#CD013348-bbs2-0121" title="WagnerAD , ArnoldD , GrotheyAAG , HaertingJ , UnverzagtS . Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD005392. [DOI: 10.1002/14651858.CD005392.pub3]">Wagner 2009</a>; <a href="./references#CD013348-bbs2-0122" title="WagnerAD , ThomssenC , HaertingJ , UnverzagtS . Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD008941. [DOI: 10.1002/14651858.CD008941.pub2]">Wagner 2012</a>). Clinical trials have shown that VEGF targeting agents improved OS or PFS but increased tolerable toxicities among women with persistent, recurrent, or metastatic cervical cancer (<a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>; <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>). This Cochrane Review aims to assess the benefits and harms of VEGF inhibitors alone or in the adjuvant setting for treatment of persistent, recurrent, or metastatic cervical cancer, with the goal of assisting clinicians and women involved in the decision‐making process. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013348-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013348-sec-0014"></div> <p>To assess the benefits and harms of VEGF targeting agents in the management of persistent, recurrent, or metastatic cervical cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013348-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013348-sec-0015"></div> <section id="CD013348-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013348-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled trials (RCTs) that evaluated use of anti‐angiogenesis therapy for persistent, recurrent, or metastatic cervical cancer. We included RCTs reported as full text, those published as abstract only, and unpublished data (no abstract only or unpublished data were found). We excluded observational studies such as case reports, case series, case‐control studies, and cohort studies. We excluded quasi‐randomised trials, cluster‐randomised trials, and cross‐over trials. </p> <p>To evaluate economics, full or partial economic evaluation studies and single effectiveness studies were considered for inclusion. This review considered only health economics studies conducted alongside effectiveness studies included in the effectiveness component of the review. </p> </section> <section id="CD013348-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adult women (aged 18 years or older) with a diagnosis of persistent, recurrent, or metastatic cervical cancer of any stage. We did not include women with any other concurrent malignancy. </p> </section> <section id="CD013348-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD013348-list-0001"> <li> <p>Vascular endothelial growth factor (VEGF) targeting agents plus other treatments versus other treatments only </p> </li> <li> <p>VEGF targeting agents versus other treatments</p> </li> <li> <p>VEGF targeting agents versus placebo or no treatment</p> </li> <li> <p>VEGF targeting agents versus other VEGF targeting agents</p> </li> </ul> </p> <p>Other treatments included standard chemotherapy, radiotherapy, other types of molecular targeted therapy, and surgery. </p> </section> <section id="CD013348-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD013348-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013348-list-0002"> <li> <p>Overall survival (OS), defined as the time interval from randomisation to death from any cause, or to last follow‐up </p> </li> <li> <p>Specific adverse events, including gastrointestinal perforations or fistulae, haemorrhage, thromboembolic events, and hypertension </p> </li> </ul> </p> </section> <section id="CD013348-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013348-list-0003"> <li> <p>Progression‐free survival (PFS), defined as the time interval from randomisation to progression of disease or death </p> </li> <li> <p>Quality of life (QoL), while on treatment and post treatment, when reported as measured on a scale that has been validated through reporting of norms in a peer‐reviewed publication (i.e. European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐CX24 cervical cancer‐specific quality of life questionnaire (<a href="./references#CD013348-bbs2-0059" title="GreimelER , Kuljanic VlasicK , WaldenstromAC , DuricVM , JensenPT , SingerS , et al. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer2006;107(8):1812-22.">Greimel 2006</a>); Functional Assessment of Cancer Therapy‐Cervix Trial Outcome Index (FACT‐Cx TOI) (www.facit.org/facitorg/); EORTC Quality Questionnaire Core 30 items (QLQ‐C30); Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System; Rotterdam Symptom Checklist (RSCL); and Symptom Distress Scale (SDS)) (<a href="./references#CD013348-bbs2-0111" title="TamburiniM . Health-related quality of life measures in cancer. Annals of Oncology2001;12(Suppl 3):S7-10.">Tamburini 2001</a>) </p> </li> <li> <p>Adverse events, classified according to <a href="./references#CD013348-bbs2-0042" title="National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 (accessed prior to 16 May 2019).">CTCAE 2017</a> </p> </li> <li> <p>Economic evaluation, as defined by individual studies, including full economic evaluation (cost‐benefit analysis, cost‐effectiveness analysis, and cost‐utility analysis), partial economic evaluation (cost analysis, cost‐description study, and cost‐outcome description), or single effectiveness evaluation (description, measurement, or valuation of resource use associated with an intervention) (<a href="./references#CD013348-bbs2-0107" title="ShemiltI , MugfordM , ByfordS , DrummondM , EisensteinE , KnappM , et al. Chapter 15. Incorporating economics evidence. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Shemilt 2011</a>) </p> </li> </ul> </p> <p>We presented a 'Summary of findings' table reporting the following outcomes listed in order of priority. </p> <p> <ul id="CD013348-list-0004"> <li> <p>Overall survival.</p> </li> <li> <p>Adverse events: gastrointestinal perforations or fistulae.</p> </li> <li> <p>Adverse events: haemorrhage.</p> </li> <li> <p>Adverse events: thromboembolic events.</p> </li> <li> <p>Adverse events: hypertension.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Economic evaluation.</p> </li> </ul> </p> </section> </section> </section> <section id="CD013348-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We applied no language or date restrictions during our searches. We searched for papers in all languages and had papers translated as necessary. </p> <section id="CD013348-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases up to 27 May 2020.</p> <p> <ul id="CD013348-list-0005"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; Issue 5, 2020), in the Cochrane Library (<a href="./appendices#CD013348-sec-0126">Appendix 1</a>); </p> </li> <li> <p>MEDLINE via Ovid (1946 to May week 3, 2020), (<a href="./appendices#CD013348-sec-0127">Appendix 2</a>); </p> </li> <li> <p>Embase via Ovid (1980 to 2020 week 21), (<a href="./appendices#CD013348-sec-0128">Appendix 3</a>). </p> </li> </ul> </p> <p>Economics search filters were not used because most of the economics studies to be considered would be retrieved using the study design search filter (<a href="./references#CD013348-bbs2-0107" title="ShemiltI , MugfordM , ByfordS , DrummondM , EisensteinE , KnappM , et al. Chapter 15. Incorporating economics evidence. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Shemilt 2011</a>). </p> </section> <section id="CD013348-sec-0025"> <h4 class="title">Searching other resources</h4> <p>All relevant articles were identified on PubMed, and we conducted a further search for newly published articles using the 'Related articles' feature. </p> <section id="CD013348-sec-0026"> <h5 class="title">Unpublished and grey literature</h5> <p>We searched the following for ongoing trials.</p> <p> <ul id="CD013348-list-0006"> <li> <p>International Standard Randomized Controlled Trials Number (ISRCTN) ‐ metaRegister of Controlled Trials <i>(</i><a href="http://www.isrctn.com/page/mrct" target="_blank">http://www.isrctn.com/page/mrct</a>). </p> </li> <li> <p>Physicians Data Query (<a href="http://www.cancer.gov/publications/pdq" target="_blank">http://www.cancer.gov/publications/pdq</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">http://www.clinicaltrials.gov</a>). </p> </li> <li> <p>International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">http://www.who.int/ictrp/en/</a>). </p> </li> </ul> </p> <p>If ongoing trials that had not been published were identified through these searches, we approached the principal investigators and major co‐operative groups active in this area to ask for relevant data. </p> <p>We also searched the reports of conferences in the Conference Proceedings Citation Index‐Science (<a href="http://mjl.clarivate.com/scope/scope_cpci-s/" target="_blank">CPCI-S</a>), along with the bibliography and abstracts in the National Health Service (NHS) Economic Evaluation Database (<a href="https://www.crd.york.ac.uk/CRDWeb/HomePage.asp" target="_blank">NHS EED</a>). </p> </section> <section id="CD013348-sec-0027"> <h5 class="title">Handsearching</h5> <p>We handsearched the citation lists of included studies, key textbooks, and previous systematic reviews, and we contacted experts in the field, to identify further reports of trials. We also handsearched the reports of conferences from the following sources. </p> <p> <ul id="CD013348-list-0007"> <li> <p><i>Gynecologic Oncology</i> (Annual Meeting of the American Society of Gynecologic Oncology). </p> </li> <li> <p><i>International Journal of Gynecological Cancer</i> (Annual Meeting of the International Gynecologic Cancer Society). </p> </li> <li> <p><i>British Journal of Cancer.</i> </p> </li> <li> <p>British Cancer Research Meeting.</p> </li> <li> <p>Annual Meeting of the European Society of Medical Oncology (ESMO).</p> </li> <li> <p>Annual Meeting of the American Society of Clinical Oncology (ASCO).</p> </li> </ul> </p> </section> </section> </section> <section id="CD013348-sec-0028"> <h3 class="title" id="CD013348-sec-0028">Data collection and analysis</h3> <section id="CD013348-sec-0029"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to a reference management database (<a href="https://endnote.com/" target="_blank">Endnote</a>), and we removed duplicates. Three review authors (YC, XZ, and IR) examined the remaining references independently. We excluded studies that clearly did not meet the inclusion criteria, and we obtained copies of the full text of potentially relevant references. Three review authors (YC, XZ, and IR) independently assessed the eligibility of retrieved reports/publications. We resolved any disagreement through discussion; if required, we consulted another person (GD). We identified and excluded duplicate reports and collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and a <a href="./references#CD013348-sec-0147" title="">Characteristics of excluded studies</a> table (<a href="./references#CD013348-bbs2-0077" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6:e1000100.">Liberati 2009</a>). </p> </section> <section id="CD013348-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (YC and XZ) independently extracted study characteristics and outcome data from included studies to a piloted data collection form. We noted in the <a href="./references#CD013348-sec-0146" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by reaching consensus or by involving a third person (GD). One review author (GD) transferred data into <a href="./references#CD013348-bbs2-0100" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>. We double‐checked that data had been entered correctly by comparing data presented in the systematic review with data provided in study reports. A second review author (YL) 'spot‐checked' the accuracy of study characteristics against the trial report. </p> <p>For included studies, we extracted the following data.</p> <p> <ul id="CD013348-list-0008"> <li> <p>Author, year of publication, and journal citation (including language).</p> </li> <li> <p>Country where the trial was performed.</p> </li> <li> <p>Study design and method.</p> </li> <li> <p>Inclusion and exclusion criteria.</p> </li> <li> <p>Study population.</p> <ul id="CD013348-list-0009"> <li> <p>Total number enrolled.</p> </li> <li> <p>Participant characteristics.</p> </li> <li> <p>Age.</p> </li> <li> <p>Comorbidities (e.g. gastrointestinal disease, cardiovascular disease).</p> </li> <li> <p>Previous therapy.</p> </li> </ul> </li> <li> <p>Cervical cancer characteristics.</p> <ul id="CD013348-list-0010"> <li> <p>FIGO stage, tumour grade, histological type of cervical cancer.</p> </li> <li> <p>Details about recurrent and metastatic disease.</p> </li> </ul> </li> <li> <p>Total number of intervention groups.</p> </li> <li> <p>Intervention details.</p> <ul id="CD013348-list-0011"> <li> <p>Type of VEGF targeting agent.</p> </li> <li> <p>Dose of VEGF targeting agent.</p> </li> <li> <p>Treatment regimen of VEGF targeting agent.</p> </li> <li> <p>Frequency and number of cycles.</p> </li> </ul> </li> <li> <p>Comparison.</p> <ul id="CD013348-list-0012"> <li> <p>Type of control.</p> </li> <li> <p>Dose, regimen, frequency and number of cycles.</p> </li> </ul> </li> <li> <p>Risk of bias in study (see below).</p> </li> <li> <p>Duration of follow‐up.</p> </li> <li> <p>Outcomes such as OS, PFS, QoL, symptom control, and adverse events.</p> </li> <li> <p>Number of participants allocated to each intervention group, total number analysed for each outcome, and missing participants. </p> </li> </ul> </p> <p>Results were extracted as follows.</p> <p> <ul id="CD013348-list-0013"> <li> <p>For time‐to‐event data (OS and PFS), we extracted the hazard ratio (HR), log of the hazard ratio [log(HR)], and its standard error (SE) from trial reports. If these were not reported, we attempted to estimate the log(HR) and its SE using the methods of <a href="./references#CD013348-bbs2-0095" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a> (e.g. number of events in each arm, log‐rank P value comparing relevant outcomes in each arm). </p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events, deaths), we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at end point, in order to estimate a risk ratio (RR). </p> </li> <li> <p>For continuous outcomes (e.g. QoL measures), we extracted the final value and the standard deviation (SD) for the outcome of interest and the number of participants assessed at end point in each treatment arm at the end of follow‐up, in order to estimate the mean difference between treatment arms and its SE. </p> </li> </ul> </p> <p>If reported, we extracted both unadjusted and adjusted statistics. If available, we would use adjusted results; otherwise we would use unadjusted results. </p> <p>When possible, all data extracted would be those relevant to an intention‐to‐treat analysis, in which participants would be analysed in the groups to which they were assigned. </p> <p>We noted the time points at which outcomes were collected and reported.</p> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary study, we maximised the yield of information by collating all available data and using the most complete data set aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> <section id="CD013348-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed and reported on the methodological risk of bias of included studies as specified in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013348-bbs2-0066" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>), which recommends explicit reporting of the following individual elements for RCTs. </p> <p> <ul id="CD013348-list-0014"> <li> <p>Selection bias: random sequence generation and allocation concealment.</p> </li> <li> <p>Performance bias: blinding of participants and personnel.</p> </li> <li> <p>Detection bias: blinding of outcome assessment.</p> </li> <li> <p>Attrition bias: incomplete outcome data.</p> </li> <li> <p>Reporting bias: selective reporting of outcomes.</p> </li> <li> <p>Other possible sources of bias.</p> </li> </ul> </p> <p>Two review authors (YC and XZ) applied the 'Risk of bias' tool independently and resolved differences by discussion with a third review author (GD). We judged each item as being at high, low, or unclear risk of bias as set out in the criteria provided by <a href="./references#CD013348-bbs2-0066" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>, and we provided a quote from the study report or a statement as justification for the judgement for each item in the 'Risk of bias' table, or both. We summarised results in both a 'Risk of bias' graph and a 'Risk of bias' summary. When interpreting treatment effects, we took into account the risk of bias for studies that contributed to that outcome. When information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. See 'Risk of bias' items (<a href="./appendices#CD013348-sec-0129">Appendix 4</a>). </p> <p>We defined the following end points as subjective outcomes: PFS, QoL.</p> <p>We defined the following end points as objective outcomes: OS, adverse events (gastrointestinal perforations and fistulae, haemorrhage, thromboembolic events, hypertension), economic evaluation. </p> </section> <section id="CD013348-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment.</p> <p> <ul id="CD013348-list-0015"> <li> <p>For time‐to‐event data, we used the HR, if possible.</p> </li> <li> <p>For dichotomous outcomes, we analysed data based on the number of events and the number of women assessed in intervention and comparison groups. We used these to calculate the RR and the 95% confidence interval (CI). </p> </li> <li> <p>For continuous outcomes, we analysed data based on the mean, the standard deviation (SD), and the number of women assessed for both intervention and comparison groups to calculate the mean difference (MD) between treatment arms with a 95% CI. If the MD was reported without individual group data, we would use this to report the study results. If more than one study measures the same outcome using different tools, we would calculate the standardised mean difference (SMD) and the 95% CI using the inverse variance method in Review Manager 5 (<a href="./references#CD013348-bbs2-0100" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </li> </ul> </p> <p>We planned to perform meta‐analysis only when this was meaningful (i.e. if treatments, participants, and the underlying clinical question were similar enough for pooling to make sense). We narratively described skewed data that were reported as medians and interquartile ranges. When multiple trial arms were reported in a single trial, we included only the relevant arms. </p> </section> <section id="CD013348-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We did not anticipate unit of analysis issues, and we noted no unit of analysis issues within the included studies. </p> </section> <section id="CD013348-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>For missing outcome or summary data, we did not impute missing data, and we reported in the review any assumptions that we made. We attempted to contact study authors to obtain missing data (participants, outcomes, or summary data). We reported on levels of loss to follow‐up and assessed this information as a source of potential bias. </p> </section> <section id="CD013348-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We did not perform an assessment of heterogeneity, as the review included only four completed trials (only one trial for each comparison), which we did not meta‐analyse. We had specified in the protocol that we planned to combine data using meta‐analysis if the studies were considered similar enough. We had intended to assess the degree of heterogeneity by visually inspecting forest plots; by estimating the percentage of heterogeneity (I² measurement) between trials that cannot be ascribed to sampling variation (<a href="./references#CD013348-bbs2-0065" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. British Medical Journal2003;357:557-60.">Higgins 2003</a>); by performing a formal statistical test of the significance of the heterogeneity (Chi²) (<a href="./references#CD013348-bbs2-0043" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London: BMJ Publication Group, 2001.">Deeks 2001</a>); and, if possible, by conducting subgroup analyses. We had intended to regard heterogeneity to be substantial if I² was greater than 30% and either T² was greater than zero or the P value was low (&lt; 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD013348-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not perform a formal assessment of potential publication bias, as the review included only four trials. We had specified in the protocol that we planned to address reporting biases according to the recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013348-bbs2-0066" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD013348-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We planned to carry out meta‐analyses by using Review Manager software (<a href="./references#CD013348-bbs2-0100" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), according to recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013348-bbs2-0066" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>), if data were sufficiently similar to be combined (in terms of participants, settings, interventions, comparisons, and outcome measures). </p> <p>Meta‐analysis was not feasible, as the review included only four completed trials (only one trial for each comparison). We noted a high degree of heterogeneity in population characteristics across trials on this topic. In future updates when meta‐analysis is feasible, we will use the random‐effects model with inverse variance weighting for all meta‐analyses (<a href="./references#CD013348-bbs2-0045" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DeSimonian 1986</a>). </p> </section> <section id="CD013348-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had considered performing subgroup analyses for the following characteristics.</p> <p> <ul id="CD013348-list-0016"> <li> <p>Different VEGF targeting agents (anti‐VEGF antibodies, VEGF trap, anti‐VEGF‐receptor antibodies, TKIs, and others). </p> </li> <li> <p>Different histological types (squamous, adenocarcinoma, and others).</p> </li> </ul> </p> <p>However, we did not perform the intended subgroup analyses, as only four studies were included (only one trial for each comparison). Although different histological types had similar survival in persistent, recurrent, or metastatic disease (<a href="./references#CD013348-bbs2-0106" title="SeamonLG , JavaJJ , MonkBJ , PensonRT , BrownJ , MannelRS , et al. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. British Journal of Cancer2018;118(2):162-70.">Seamon 2018</a>), we considered this factor when interpreting the OS. </p> </section> <section id="CD013348-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to re‐analyse data using a random‐effects model instead of a fixed‐effect model. We had planned to re‐analyse data by including/excluding studies on the basis of differences in risk of bias, quality components (full‐text publications versus abstracts and preliminary results versus mature results), participant dropout, and missing data. However, only four studies (one trial for each comparison) were included, so sensitivity analysis was not possible. </p> </section> <section id="CD013348-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall certainty of the evidence for prespecified outcomes (<a href="#CD013348-sec-0020">Types of outcome measures</a>), including overall survival, adverse events, and economic evaluation, according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, which takes into account issues not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity such as directness of results (<a href="./references#CD013348-bbs2-0076" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchunemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;23(2):81.">Langendam 2013</a>)<i>.</i> We created 'Summary of findings' tables (<a href="./full#CD013348-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD013348-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD013348-tbl-0003">summary of findings Table 3</a>, <a href="./full#CD013348-tbl-0004">summary of findings Table 4</a>, <a href="./full#CD013348-tbl-0005">summary of findings Table 5</a>) based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013348-bbs2-0066" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>) and using <a href="http://gradepro.org/" target="_blank">GRADEpro GDT</a>. We used the GRADE checklist and GRADE Working Group certainty of evidence definitions (<a href="./references#CD013348-bbs2-0083" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82.">Meader 2014</a>; <a href="./references#CD013348-bbs2-0062" title="GyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: introduction to GRADE evidence profiles and summary of findings. Journal of Clinical Epidemiology2011;64(4):383-94. [available at http://cccrg.cochrane.org/author-resources]">Gyatt 2011</a>). We downgraded the evidence from 'high' certainty by one level for serious (or by two for very serious) concerns for each limitation for the outcomes detailed under <a href="#CD013348-sec-0020">Types of outcome measures</a>: </p> <p> <ul id="CD013348-list-0017"> <li> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect; </p> </li> <li> <p><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; </p> </li> <li> <p><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; </p> </li> <li> <p><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013348-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013348-sec-0041"></div> <section id="CD013348-sec-0042"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD013348-sec-0146" title="">Characteristics of included studies,</a><a href="./references#CD013348-sec-0147" title="">Characteristics of excluded studies,</a><a href="./references#CD013348-sec-0148" title="">Characteristics of studies awaiting classification,</a> and <a href="./references#CD013348-sec-0149" title="">Characteristics of ongoing studies</a>. </p> <section id="CD013348-sec-0043"> <h4 class="title">Results of the search</h4> <p>The literature search was designed to find all relevant references about vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. Through the main database searches, we identified 1752 records; we identified an additional 43 records by searching other sources. After removing duplicates, we screened 1634 unique records for eligibility and excluded 1576 records during the initial screening process; we assessed the full text or abstract of the remaining 58 records. We identified 28 references related to four studies that fulfilled the inclusion criteria and were included in the review. The study flow diagram in <a href="#CD013348-fig-0002">Figure 2</a> provides an overview of the study selection process. </p> <div class="figure" id="CD013348-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013348-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013348-sec-0044"> <h4 class="title">Included studies</h4> <p>We included four studies that fulfilled the inclusion criteria of this review (<a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>; <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>). <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> and <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> used the VEGF targeting agents anti‐VEGF antibody and tyrosine kinase inhibitor (TKI) of VEGF receptor (VEGF‐R), respectively, plus cisplatin/paclitaxel chemotherapy versus chemotherapy only (<a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>), or versus placebo (<a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>). <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> used VEGF targeting agent (TKI of VEGF‐R) plus chemotherapy (carboplatin and paclitaxel) or chemoradiotherapy versus chemotherapy or chemoradiotherapy only. <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> used VEGF targeting agent (TKI of VEGF‐R) alone or another molecular targeted therapy agent (TKI of epidermal growth factor receptor and human epidermal growth factor receptor 2) versus a combination of both targeted agents. See <a href="./references#CD013348-sec-0146" title="">Characteristics of included studies</a> for full details of each study. </p> <section id="CD013348-sec-0045"> <h5 class="title">Study design and methods</h5> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> was an open‐label study reporting that participants were randomly assigned to receive cisplatin/paclitaxel chemotherapy with or without bevacizumab, or topotecan/paclitaxel chemotherapy with or without bevacizumab. <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> was a double‐blind study reporting that participants were randomly assigned 1:1 to receive carboplatin/paclitaxel chemotherapy with cediranib or placebo. <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> was an open‐label study reporting that participants were randomly assigned 1:1 to receive chemotherapy or chemoradiotherapy with or without apatinib. <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> was an open‐label study reporting that participants were randomly assigned 1:1:1 to receive pazopanib or lapatinib, or both. </p> </section> <section id="CD013348-sec-0046"> <h5 class="title">Sample sizes and participants</h5> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> included 452 participants: 227 in the intervention arm and 225 in the control arm; 452 were randomised and 440 received study treatment; median age was 48 years (range 20 to 85 years); histological types included squamous (N = 310), adenocarcinoma (N = 86), and other (N = 56); disease sites and extents included pelvic disease (N = 242) and extra‐pelvic disease (N = 210). </p> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> included 69 participants: 69 randomised and 67 receiving study treatment; median age was 43.5 years and interquartile range (IQR) 37 to 60 years in the intervention arm; median age was 44 years and IQR 34 to 53 years in the control arm; histological types included squamous (N = 47), adenocarcinoma (N = 14), and other (N = 8); disease sites and extents included local relapse only (N = 9), extra‐pelvic metastases only (N = 21), and both (N = 39). </p> <p><a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> included 59 participants with recurrent and advanced cervical cancer who were randomised to the apatinib group (N = 30) and the control group (N = 29); median age was 49.5 years (range 28 to 62 years) in the intervention arm and 51 years (range 30 to 69 years) in the control arm; histological types included squamous (N = 44) and adenocarcinoma (N = 8); 34 of 52 participants had more than two extra‐pelvic disease sites (59 were randomised; 52 were included in the analysis). </p> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> included 228 participants: 228 were randomised and 226 received study treatment; median age was 49.5 years (range 29 to 73 years) in the pazopanib arm, 49 years (range 23 to 81 years) in the lapatinib arm, and 48.5 years (range 28 to 82 years) in the pazopanib plus lapatinib arm; histological types included squamous (N = 151), adenocarcinoma (N = 42), and other (N = 35); 213 received prior anti‐cancer therapies. </p> </section> <section id="CD013348-sec-0047"> <h5 class="title">Setting</h5> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> was conducted at 81 sites in the USA, Canada, and Spain. <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> was conducted at 17 sites in the UK. <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> was conducted at a single centre in China. <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> was conducted at 50 sites in the USA, Europe, South America, and Asia. </p> </section> <section id="CD013348-sec-0048"> <h5 class="title">Interventions</h5> <p>In <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, participants were randomised to receive cisplatin (50 mg/m²) plus paclitaxel (135 or 175 mg/m²) with or without bevacizumab (15 mg/kg) intravenously, or topotecan (0.75 mg/m², days 1 to 3) plus paclitaxel (175 mg/m²) with or without bevacizumab (15 mg/kg) intravenously, for each 21‐day chemotherapy cycle until disease progression or unacceptable toxicity. </p> <p>In <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, participants were randomised to receive carboplatin (area under the curve (AUC) of free carboplatin plasma concentration versus time (<a href="./references#CD013348-bbs2-0034" title="CalvertAH , NewellDR , GumbrellLA , O'ReillyS , BurnellM , BoxallFE , et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. Journal of Clinical Oncology 1989 Nov;7(11):1748-56.">Calvert 1989</a>), AUC 5 mg/mL/min) plus paclitaxel (175 mg/m²) with cediranib (20 mg) or placebo orally once daily, for each 21‐day chemotherapy cycle and for a maximum of six cycles, plus cediranib or placebo 20 mg orally once daily until disease progression or unacceptable toxicity. </p> <p>In <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, participants with recurrent disease were randomised to carboplatin (AUC 5 mg/mL/min) plus paclitaxel (135 to 175 mg/m²) with or without apatinib (500 mg orally once daily) for each 21‐day chemotherapy cycle and for a maximum of six cycles until disease progression or unacceptable toxicity; participants with stage IVB disease were randomised to carboplatin (AUC 5 mg/mL/min) plus paclitaxel (135 to 175 mg/m²) plus brachytherapy (intracavity radiotherapy) (total 50 to 60 Gy) with or without apatinib (500 mg orally once daily) for each 21‐day chemotherapy cycle and for a maximum of six cycles until disease progression or unacceptable toxicity. </p> <p>In <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, participants were randomised to receive pazopanib (800 mg) or lapatinib (1500 mg), or both, orally daily until disease progression or unacceptable toxicity. </p> </section> <section id="CD013348-sec-0049"> <h5 class="title">Outcomes</h5> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> reported overall survival (OS), progression‐free survival (PFS), quality of life (QoL), adverse events, and economic evaluation, with maximum follow‐up longer than 50 months for OS. Moore criteria were used to assess the level of risk of death (<a href="./references#CD013348-bbs2-0090" title="MooreDH , TianC , MonkBJ , LongHJ , OmuraGA , BlossJD . Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecologic Oncology2010;116(1):44-9.">Moore 2010</a>). These criteria include five negative factors: ethnicity, performance status 1, pelvic disease, prior cisplatin, and progression‐free interval less than 365 days. Risk categories included low risk (zero to one factor), medium risk (two to three factors), and high risk (four to five factors). QoL was measured using the Trial Outcome of Index of the Functional Assessment of Cancer Therapy (FACT‐Cx‐TOI) (<a href="./references#CD013348-bbs2-0040" title="CellaDF , TulskyDS , GrayG , SarafianB , LinnE , BonomiA , et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology1993;11(3):570-9.">Cella 1993</a>), the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group‐Neurotoxicity (FACT/GOG‐NTX) (<a href="./references#CD013348-bbs2-0067" title="HuangHQ , BradyMF , CellaD , FlemingG . Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. International Journal of Gynecological Cancer2007;17(2):387-93.">Huang 2007</a>), and the Brief Pain Inventory (BPI) (<a href="./references#CD013348-bbs2-0041" title="CleelandCS , RyanKM . Pain assessment: global use of the Brief Pain Inventory. Annals of the Academy of Medicine Singapore1994;23(2):129-38.">Cleeland 1994</a>). Specific adverse events included gastrointestinal perforations or fistulae, serious haemorrhage, serious thromboembolic events, and hypertension. </p> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> reported OS, PFS, QoL, and adverse events, with median follow‐up of 24.2 months for OS. QoL was measured using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐C30 questionnaire (<a href="./references#CD013348-bbs2-0023" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365-76.">Aaronson 1993</a>). Specific adverse events included gastrointestinal perforations or fistulae, serious haemorrhage, serious thromboembolic events, and serious hypertension. </p> <p><a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> reported OS, PFS, and hypertension events, with median follow‐up of 14 months for OS. </p> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported OS, PFS, and adverse events, with maximum follow‐up longer than 150 weeks for OS. Specific adverse events included gastrointestinal perforations or fistulae, haemorrhage, thromboembolic events, and hypertension. </p> </section> </section> <section id="CD013348-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded seven studies (<a href="./references#CD013348-bbs2-0005" title='Godoy-OrtizA , PlataY , AlcaideJ , GaleoteA , PajaresB , SaezE , et al. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients. Clinical and Translational Oncology2018;20(7):922-7. '>Godoy‐Ortiz 2018</a>; <a href="./references#CD013348-bbs2-0006" title="2018-000367-83. Chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus chemotherapy plus paclitaxel and bevacizumab in carcinoma of the cervix. EU Clinical Trials Register (accessed 2 December 2019). GrauJF , Farinas-MadridL , OakninA . A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). International Journal of Gynecological Cancer2020;30(1):139-43. JPRN-jRCT2041190037. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix (BEATcc). Japan Registry of Clinical Trials (accessed 2 December 2019). NCT03556839. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix (BEATcc). ClinicalTrials.gov (accessed 2 December 2019). OakninA , GladieffL , ColomboN , VillacampaG , MirzaMR , De GiorgiU , et al. BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): a randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx). Journal of Clinical Oncology2019;37(Suppl 15):TP5594. ">Grau 2020</a>; <a href="./references#CD013348-bbs2-0007" title="2016-004215-13. Randomised phase II trial of cediranib and olaparib maintenance in advanced/recurrent cervical cancer (COMICE). EU Clinical Trials Register (accessed 2 December 2019). ISRCTN10841582. COMICE: a randomised double blind placebo controlled phase II clinical trial of cediranib and olaparib maintenance in advanced/recurrent cervical cancer. ISRCTN Registry (accessed 2 December 2019). ">ISRCTN10841582</a>; <a href="./references#CD013348-bbs2-0008" title="IshikawaM , NakamuraK , ShibataT , TanakaK , KitagawaR , KobayashiH , et al. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311). Japanese Journal of Clinical Oncology2018;48(12):1096-100. JPRN-jRCTs031180007. Randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311, CC-TC/ddTC-P2/3). Japan Registry of Clinical Trials (accessed 2 December 2019). KitagawaR , IshikawaM , ShibataT , MiyamotoK , KobayashiH , OndaT , et al. A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311). Journal of Clinical Oncology2018;Conference: 2018 Annual Meeting of the American Society of Clinical Oncology(15):Suppl 1. ">JPRN‐jRCTs031180007</a>; <a href="./references#CD013348-bbs2-0009" title="FujiwaraK , Shapira-FrommerR , AlexandreJ , MonkB , FehmT , ColomboN , et al. KEYNOTE-826: a phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer. Annals of Oncology2019;30(Suppl 9):89-90. NCT03635567. Efficacy and safety study of first-line treatment with pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy in women with persistent, recurrent, or metastatic cervical cancer (MK-3475-826/KEYNOTE-826). ClinicalTrials.gov (accessed 2 December 2019). Shapira-FrommerR , AlexandreJ , MonkB , FehmTN , ColomboN , CaceresMV , et al. KEYNOTE826: a phase 3, randomized, double blind, placebo controlled study of pembrolizumab plus chemotherapy for first line treatment of persistent, recurrent, or metastatic cervical cancer. Journal of Clinical Oncology2019;37(Suppl 15):TP5595. TewariK , CaceresMV , AlexandreJ , MonkB , FehmT , ColomboN , et al. KEYNOTE-826: a phase 3, randomized, double blind, placebo-controlled study of pembrolizumab plus chemotherapy for first line treatment of persistent, recurrent, or metastatic cervical cancer. International Journal of Gynecological Cancer2019;29(Suppl 3):A162. ">NCT03635567</a>; <a href="./references#CD013348-bbs2-0010" title="NCT03912415. Efficacy and safety of BCD-100 (anti-PD-1) in combination with platinum-based chemotherapy with and without bevacizumab as first-line treatment of subjects with advanced cervical cancer (FERMATA). ClinicalTrials.gov (accessed 2 December 2019). ">NCT03912415</a>; <a href="./references#CD013348-bbs2-0011" title="PhippenNT , LeathCA , HavrileskyLJ , BarnettJC . Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?Gynecologic Oncology2015;136(1):43-7. ">Phippen 2015</a>). Five studies were not relevant comparisons (VEGF targeting agents alone or in combination with other treatments versus placebo, no treatment, other treatments, or another VEGF targeting agent) (<a href="./references#CD013348-bbs2-0006" title="2018-000367-83. Chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus chemotherapy plus paclitaxel and bevacizumab in carcinoma of the cervix. EU Clinical Trials Register (accessed 2 December 2019). GrauJF , Farinas-MadridL , OakninA . A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). International Journal of Gynecological Cancer2020;30(1):139-43. JPRN-jRCT2041190037. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix (BEATcc). Japan Registry of Clinical Trials (accessed 2 December 2019). NCT03556839. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix (BEATcc). ClinicalTrials.gov (accessed 2 December 2019). OakninA , GladieffL , ColomboN , VillacampaG , MirzaMR , De GiorgiU , et al. BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): a randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx). Journal of Clinical Oncology2019;37(Suppl 15):TP5594. ">Grau 2020</a>; <a href="./references#CD013348-bbs2-0007" title="2016-004215-13. Randomised phase II trial of cediranib and olaparib maintenance in advanced/recurrent cervical cancer (COMICE). EU Clinical Trials Register (accessed 2 December 2019). ISRCTN10841582. COMICE: a randomised double blind placebo controlled phase II clinical trial of cediranib and olaparib maintenance in advanced/recurrent cervical cancer. ISRCTN Registry (accessed 2 December 2019). ">ISRCTN10841582</a>; <a href="./references#CD013348-bbs2-0008" title="IshikawaM , NakamuraK , ShibataT , TanakaK , KitagawaR , KobayashiH , et al. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311). Japanese Journal of Clinical Oncology2018;48(12):1096-100. JPRN-jRCTs031180007. Randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311, CC-TC/ddTC-P2/3). Japan Registry of Clinical Trials (accessed 2 December 2019). KitagawaR , IshikawaM , ShibataT , MiyamotoK , KobayashiH , OndaT , et al. A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311). Journal of Clinical Oncology2018;Conference: 2018 Annual Meeting of the American Society of Clinical Oncology(15):Suppl 1. ">JPRN‐jRCTs031180007</a>; <a href="./references#CD013348-bbs2-0009" title="FujiwaraK , Shapira-FrommerR , AlexandreJ , MonkB , FehmT , ColomboN , et al. KEYNOTE-826: a phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer. Annals of Oncology2019;30(Suppl 9):89-90. NCT03635567. Efficacy and safety study of first-line treatment with pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy in women with persistent, recurrent, or metastatic cervical cancer (MK-3475-826/KEYNOTE-826). ClinicalTrials.gov (accessed 2 December 2019). Shapira-FrommerR , AlexandreJ , MonkB , FehmTN , ColomboN , CaceresMV , et al. KEYNOTE826: a phase 3, randomized, double blind, placebo controlled study of pembrolizumab plus chemotherapy for first line treatment of persistent, recurrent, or metastatic cervical cancer. Journal of Clinical Oncology2019;37(Suppl 15):TP5595. TewariK , CaceresMV , AlexandreJ , MonkB , FehmT , ColomboN , et al. KEYNOTE-826: a phase 3, randomized, double blind, placebo-controlled study of pembrolizumab plus chemotherapy for first line treatment of persistent, recurrent, or metastatic cervical cancer. International Journal of Gynecological Cancer2019;29(Suppl 3):A162. ">NCT03635567</a>; <a href="./references#CD013348-bbs2-0010" title="NCT03912415. Efficacy and safety of BCD-100 (anti-PD-1) in combination with platinum-based chemotherapy with and without bevacizumab as first-line treatment of subjects with advanced cervical cancer (FERMATA). ClinicalTrials.gov (accessed 2 December 2019). ">NCT03912415</a>). Two studies were not RCTs (<a href="./references#CD013348-bbs2-0005" title='Godoy-OrtizA , PlataY , AlcaideJ , GaleoteA , PajaresB , SaezE , et al. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients. Clinical and Translational Oncology2018;20(7):922-7. '>Godoy‐Ortiz 2018</a>; <a href="./references#CD013348-bbs2-0011" title="PhippenNT , LeathCA , HavrileskyLJ , BarnettJC . Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?Gynecologic Oncology2015;136(1):43-7. ">Phippen 2015</a>). </p> <section id="CD013348-sec-0051"> <h5 class="title">Studies awaiting classification</h5> <p>The review authors found one completed study comparing TKI of VEGF‐R (apatinib) plus chemoradiotherapy with chemoradiotherapy alone for women (40 participants) with FIGO stage IIB to IV cervical cancer (<a href="./references#CD013348-bbs2-0012" title="RaoL , XiaC , XieZ , ZhangT , CuiC , ChenJ , et al. Clinical efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of advanced cervical cancer (Chinese). Anti-tumor Pharmacy2018;8(5):767-71. ">Rao 2018</a>). <a href="./references#CD013348-bbs2-0012" title="RaoL , XiaC , XieZ , ZhangT , CuiC , ChenJ , et al. Clinical efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of advanced cervical cancer (Chinese). Anti-tumor Pharmacy2018;8(5):767-71. ">Rao 2018</a> reported the median OS in the apatinib group was 19.88 months versus 10.68 in the control group (P = 0.022). The review authors found a second completed study that compared bevacizumab plus chemoradiotherapy with chemoradiotherapy alone for women (75 participants) with advanced cervical adenocarcinoma but did not address OS (<a href="./references#CD013348-bbs2-0013" title="XieZ , WanY . Efficacy of bevacizumab combined with cisplatin chemotherapy and definitive radiotherapy in treatment of advanced cervical adenocarcinoma (Chinese). Journal of Practical Oncology2016;31(5):455-8. ">Xie 2016</a>). However, trial registration details were not found for the two studies, and contacting the principal Investigators did not result in the receipt of any additional data. </p> <p>The review authors found nine ongoing studies (<a href="./references#CD013348-bbs2-0014" title="ChiCTR1800017291. A phase II prospective, multicenter, randomized controlled trial for maintenance therapy of apatinib combined with capecitabine for recurrent/metastatic and persistent cervical cancer after chemoradiotherapy. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1800017291</a>; <a href="./references#CD013348-bbs2-0015" title="ChiCTR1800017846. First-line chemotherapy combined with or without apatinib in patients with primary recurrence of cervical cancer. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1800017846</a>; <a href="./references#CD013348-bbs2-0016" title="ChiCTR1800018232. Aapatinib plus paclitaxel and cisplatin/carboplatin versus paclitaxel and cisplatin/carboplatin in the treatment of stage IVB, recurrent or persistent cervical cancer: a prospective, randomized, multicenter, phase II clinical study. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1800018232</a>; <a href="./references#CD013348-bbs2-0017" title="ChiCTR1900020912. Phase II clinical study for anlotinib combined with gemcitabine in the treatment of recurrent or metastatic advanced cervical cancer. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1900020912</a>; <a href="./references#CD013348-bbs2-0018" title="ChiCTR1900021190. A prospective, exploratory, single-center clinical study for anlotinib hydrochloride combined with chemotherapy versus chemotherapy alone for advanced, recurrent, and persistent vaginal cancer, cervical cancer, and uterine malignancies. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1900021190</a>; <a href="./references#CD013348-bbs2-0019" title="ChiCTR1900025465. Efficacy and safety of carillizumab combined with apatinib mesylate and concurrent chemoradiotherapy in the treatment of IVB cervical cancer. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1900025465</a>; <a href="./references#CD013348-bbs2-0020" title="ChiCTR1900025992. A randomized, controlled and open clinical study for TC regimen, TC regimen combined with apatinib or TC regimen combined with SHR-1210 in the treatment of advanced and recurrent cervical cancer. Chinese Clinical Trial Registry (accessed 1 April 2020). ">ChiCTR1900025992</a>; <a href="./references#CD013348-bbs2-0021" title='2012-004076-19. ENGOT-cx1/BGOG-cx1. "Randomized double-blind Phase II study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma". EU Clinical Trials Register (accessed 2 December 2019). NCT02009579. BGOG-cx1/ENGOT-cx1. Randomized double-blind phase II study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma. ClinicalTrials.gov (accessed 2 December 2019). '>NCT02009579</a>; <a href="./references#CD013348-bbs2-0022" title="ChiCTR-OIN-17012164. The efficacy and safety of apatinib as second-line for advanced recurrent cervical cancer (AARCA). Chinese Clinical Trial Registry (accessed 2 December 2019). ZhouJG , ZhouNJ , ZhangQ , FengYY , ZhouH . Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial. Trials2018;19(1):500. ">Zhou 2018</a>) for TKI of VEGF‐R. These studies have not to date reported any outcomes. </p> <p> <ul id="CD013348-list-0018"> <li> <p>TKI of VEGF‐R plus chemotherapy versus chemotherapy: apatinib (<a href="./references#CD013348-bbs2-0014" title="ChiCTR1800017291. A phase II prospective, multicenter, randomized controlled trial for maintenance therapy of apatinib combined with capecitabine for recurrent/metastatic and persistent cervical cancer after chemoradiotherapy. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1800017291</a>; <a href="./references#CD013348-bbs2-0015" title="ChiCTR1800017846. First-line chemotherapy combined with or without apatinib in patients with primary recurrence of cervical cancer. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1800017846</a>; <a href="./references#CD013348-bbs2-0016" title="ChiCTR1800018232. Aapatinib plus paclitaxel and cisplatin/carboplatin versus paclitaxel and cisplatin/carboplatin in the treatment of stage IVB, recurrent or persistent cervical cancer: a prospective, randomized, multicenter, phase II clinical study. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1800018232</a>; <a href="./references#CD013348-bbs2-0020" title="ChiCTR1900025992. A randomized, controlled and open clinical study for TC regimen, TC regimen combined with apatinib or TC regimen combined with SHR-1210 in the treatment of advanced and recurrent cervical cancer. Chinese Clinical Trial Registry (accessed 1 April 2020). ">ChiCTR1900025992</a>), anlotinib (<a href="./references#CD013348-bbs2-0017" title="ChiCTR1900020912. Phase II clinical study for anlotinib combined with gemcitabine in the treatment of recurrent or metastatic advanced cervical cancer. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1900020912</a>; <a href="./references#CD013348-bbs2-0018" title="ChiCTR1900021190. A prospective, exploratory, single-center clinical study for anlotinib hydrochloride combined with chemotherapy versus chemotherapy alone for advanced, recurrent, and persistent vaginal cancer, cervical cancer, and uterine malignancies. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1900021190</a>), nintedanib (<a href="./references#CD013348-bbs2-0021" title='2012-004076-19. ENGOT-cx1/BGOG-cx1. "Randomized double-blind Phase II study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma". EU Clinical Trials Register (accessed 2 December 2019). NCT02009579. BGOG-cx1/ENGOT-cx1. Randomized double-blind phase II study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma. ClinicalTrials.gov (accessed 2 December 2019). '>NCT02009579</a>): expected recruitment 698 participants. </p> </li> <li> <p>TKI of VEGF‐R plus chemotherapy versus anti‐programmed death 1 (PD‐1) antibody plus chemotherapy: apatinib (<a href="./references#CD013348-bbs2-0020" title="ChiCTR1900025992. A randomized, controlled and open clinical study for TC regimen, TC regimen combined with apatinib or TC regimen combined with SHR-1210 in the treatment of advanced and recurrent cervical cancer. Chinese Clinical Trial Registry (accessed 1 April 2020). ">ChiCTR1900025992</a>): expected recruitment 72 participants. </p> </li> <li> <p>TKI of VEGF‐R plus chemoradiotherapy versus anti‐PD‐1 antibody plus chemoradiotherapy versus TKI of VEGF‐R plus anti‐PD‐1 antibody plus chemoradiotherapy: apatinib (<a href="./references#CD013348-bbs2-0019" title="ChiCTR1900025465. Efficacy and safety of carillizumab combined with apatinib mesylate and concurrent chemoradiotherapy in the treatment of IVB cervical cancer. Chinese Clinical Trial Registry (accessed 2 December 2019). ">ChiCTR1900025465</a>): expected recruitment 60 participants. </p> </li> <li> <p>TKI of VEGF‐R versus supportive care: apatinib (<a href="./references#CD013348-bbs2-0022" title="ChiCTR-OIN-17012164. The efficacy and safety of apatinib as second-line for advanced recurrent cervical cancer (AARCA). Chinese Clinical Trial Registry (accessed 2 December 2019). ZhouJG , ZhouNJ , ZhangQ , FengYY , ZhouH . Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial. Trials2018;19(1):500. ">Zhou 2018</a>): expected recruitment 60 participants. </p> </li> </ul> </p> </section> </section> </section> <section id="CD013348-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of included studies is summarised in <a href="#CD013348-fig-0003">Figure 3</a> and <a href="#CD013348-fig-0004">Figure 4</a> (<a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>; <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>; <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>). See the 'Risk of bias' tables within <a href="./references#CD013348-sec-0146" title="">Characteristics of included studies</a> for assessment details. </p> <div class="figure" id="CD013348-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013348-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013348-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013348-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013348-sec-0053"> <h4 class="title">Allocation</h4> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, and <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> were judged as having adequate allocation concealment. Participants were randomly assigned by validated randomisation systems. </p> <p>In <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, information about random sequence generation or allocation concealment was not available. We assessed this study to be at unclear risk of selection bias. </p> </section> <section id="CD013348-sec-0054"> <h4 class="title">Blinding</h4> <p><a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, and <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> were reported as 'open‐label'; we assessed their risk of bias arising from lack of blinding of participants, investigators, and outcomes assessors as low for objective outcomes (i.e. OS, adverse events, and economic evaluation), and we assessed their risk as high for subjective outcomes (i.e. PFS and QoL). <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> was reported as 'double‐blind'; we assessed this study to be at low risk of bias for both objective and subjective outcomes. </p> </section> <section id="CD013348-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, and <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> included all participants who were randomised and received study medications for the analyses. In <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, 88% of women were assessed in the analysis (59 participants were randomised, and 52 were included in the analysis). We assessed these studies to be at low risk of attrition bias. </p> </section> <section id="CD013348-sec-0056"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, and <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> protocols were available and reported primary outcomes. Outcomes in the study protocols were the same as those finally reported in the publications. We assessed these studies to be at low risk of selective reporting bias. </p> <p>For <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, trial registration occurred later than study completion. We assessed this study to be at high risk of selective reporting bias. </p> </section> <section id="CD013348-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>The study on apatinib was sponsored by HengRui Medicine, the manufacturer of apatinib (<a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>). The study on pazopanib was sponsored by GlaxoSmithKline, the manufacturer of pazopanib (<a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>). Economic evaluation was not a planned analysis in the study protocol for <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>. </p> </section> </section> <section id="CD013348-sec-0058"> <h3 class="title" id="CD013348-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD013348-tbl-0001"><b>Summary of findings 1</b> Bevacizumab plus chemotherapy compared to chemotherapy</a>; <a href="./full#CD013348-tbl-0002"><b>Summary of findings 2</b> Cediranib plus chemotherapy compared to placebo plus chemotherapy</a>; <a href="./full#CD013348-tbl-0003"><b>Summary of findings 3</b> Apatinib plus chemotherapy or chemotherapy/brachytherapy compared to chemotherapy or chemotherapy/brachytherapy</a>; <a href="./full#CD013348-tbl-0004"><b>Summary of findings 4</b> Pazopanib plus lapatinib compared to lapatinib</a>; <a href="./full#CD013348-tbl-0005"><b>Summary of findings 5</b> Pazopanib compared to lapatinib</a> </p> <section id="CD013348-sec-0059"> <h4 class="title">Bevacizumab plus chemotherapy versus chemotherapy only</h4> <section id="CD013348-sec-0060"> <h5 class="title">Overall survival</h5> <p>In <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, treatment with bevacizumab plus chemotherapy may have resulted in lower risk of death compared to chemotherapy alone (hazard ratio (HR) 0.77, 95% confidence interval (CI) 0.62 to 0.95; 1 study, 452 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0005" title="">Analysis 1.1</a><a href="./full#CD013348-tbl-0001">summary of findings Table 1</a>). <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> reported median overall survival (OS) in the bevacizumab groups as 16.8 months (mortality rate 170/227 participants) and median OS in the control groups as 13.3 months (mortality rate 178/225 participants). </p> <p>Two hundred seventy‐one participants died (131/227 in the bevacizumab groups, 140/225 in the control groups). </p> <p> <ul id="CD013348-list-0019"> <li> <p>Bevacizumab reduced risk of death in the pelvic disease subgroup (N = 242) but had no effect and appreciable benefit for the extra‐pelvic disease subgroup (N = 210) (details of HR and CI were not provided). </p> </li> <li> <p>Bevacizumab reduced risk of death in the squamous subgroup (N = 310) but had appreciable benefit and harm for non‐squamous subgroups (adenocarcinoma N = 86, adenosquamous N = 44, others N = 12) (details of HR and CI were not provided). </p> </li> </ul> </p> <p>Moore criteria included the following.</p> <p> <ul id="CD013348-list-0020"> <li> <p>Low‐risk population: for risk of death, HR was 0.96 (95% CI 0.51 to 1.83); median OS was 22.9 months in the bevacizumab groups (mortality rate 17/40 participants) and 21.8 months in the control groups (mortality rate 21/44 participants). </p> </li> <li> <p>Medium‐risk population: treatment with bevacizumab plus chemotherapy may result in lower risk of death compared to chemotherapy alone (HR 0.67, 95% CI 0.51 to 0.91); median OS was 17.9 months in the bevacizumab groups (mortality rate 84/152 participants) and 12.1 months in the control groups (mortality rate 92/151 participants). </p> </li> <li> <p>High‐risk population: treatment with bevacizumab plus chemotherapy may result in lower risk of death compared to chemotherapy alone (HR 0.54, 95% CI 0.32 to 0.91); median OS was 12.1 months in the bevacizumab groups (mortality rate 30/35 participants) and 6.3 months in the control groups (mortality rate 27/30 participants). </p> </li> </ul> </p> </section> <section id="CD013348-sec-0061"> <h5 class="title">Specific adverse events</h5> <section id="CD013348-sec-0062"> <h6 class="title">Gastrointestinal perforations or fistulae</h6> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> reported a higher incidence of gastrointestinal perforations or fistulae in 18 of 220 participants (at least 18) receiving bevacizumab plus chemotherapy compared to 1 of 220 participants receiving chemotherapy alone (risk ratio (RR) 18.00, 95% CI 2.42 to 133.67; 1 study, 440 participants; moderate‐certainty evidence; <a href="./references#CD013348-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD013348-sec-0063"> <h6 class="title">Haemorrhage</h6> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> reported a higher incidence of serious haemorrhage in 10 of 220 participants receiving bevacizumab plus chemotherapy compared to 2 of 220 participants receiving chemotherapy alone (RR 5.00, 95% CI 1.11 to 22.56; 1 study, 440 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD013348-sec-0064"> <h6 class="title">Thromboembolic events</h6> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> reported a higher incidence of serious thromboembolic events in 18 of 220 participants receiving bevacizumab plus chemotherapy compared to 4 of 220 participants receiving chemotherapy alone (RR 4.5, 95% CI 1.55 to 13.08; 1 study, 440 participants; moderate‐certainty evidence; <a href="./references#CD013348-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD013348-sec-0065"> <h6 class="title">Hypertension</h6> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> reported a higher incidence of hypertension in 55 of 220 participants receiving bevacizumab plus chemotherapy compared to 4 of 220 participants receiving chemotherapy alone (RR 13.75, 95% CI 5.07 to 37.29; 1 study, 440 participants; moderate‐certainty evidence; <a href="./references#CD013348-fig-0009" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD013348-sec-0066"> <h5 class="title">Progression‐free survival</h5> <p>In <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, treatment with bevacizumab plus chemotherapy resulted in lower risk of disease progression compared to chemotherapy alone (HR 0.68, 95% CI 0.56 to 0.83; 1 study, 452 participants; <a href="./references#CD013348-fig-0010" title="">Analysis 1.6</a>). <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> reported median progression‐free survival (PFS) as 8.2 months in the bevacizumab groups (morbidity rate 199/227 participants) and as 6.0 months in the control groups (morbidity rate 206/225 participants). </p> </section> <section id="CD013348-sec-0067"> <h5 class="title">Quality of life</h5> <p>In <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, participants were assessed at five time points with the Trial Outcome of Index of the Functional Assessment of Cancer Therapy (FACT‐Cx‐TOI) (<a href="./references#CD013348-bbs2-0040" title="CellaDF , TulskyDS , GrayG , SarafianB , LinnE , BonomiA , et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology1993;11(3):570-9.">Cella 1993</a>), the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group‐Neurotoxicity (FACT/GOG‐NTX) (<a href="./references#CD013348-bbs2-0067" title="HuangHQ , BradyMF , CellaD , FlemingG . Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. International Journal of Gynecological Cancer2007;17(2):387-93.">Huang 2007</a>), and the Brief Pain Inventory (BPI) (<a href="./references#CD013348-bbs2-0041" title="CleelandCS , RyanKM . Pain assessment: global use of the Brief Pain Inventory. Annals of the Academy of Medicine Singapore1994;23(2):129-38.">Cleeland 1994</a>). There was no difference in quality of life (QoL) (FACT‐Cx‐TOI scores) with or without bevacizumab (mean difference (MD) ‐1.2, 98.75% CI ‐4.1 to 1.7; 390 participants). There may or not have been a difference in neurotoxicity (FACT/GOG‐NTX scores) with or without bevacizumab (MD 0.23, 98.75% CI ‐1.19 to 1.64; 390 participants). There may or may not have been a difference in pain (BPI) with or without bevacizumab (MD 0.5, 95% CI ‐0.14 to 1.14; 390 participants). </p> </section> <section id="CD013348-sec-0068"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> reported total adverse events in 218 of 220 participants receiving bevacizumab plus chemotherapy and in 219 of 219 participants receiving chemotherapy alone (RR 0.99, 95% CI 0.98 to 1.01; 1 study, 439 participants; <a href="./references#CD013348-fig-0012" title="">Analysis 1.8</a>). However, treatment with bevacizumab plus chemotherapy (114/220) probably resulted in a higher incidence of serious adverse events compared to chemotherapy alone (79/219) (RR 1.44, 95% CI 1.16 to 1.79; 1 study, 439 participants; moderate‐certainty evidence; <a href="./references#CD013348-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD013348-sec-0069"> <h5 class="title">Economic evaluation</h5> <p>In <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, study authors evaluated the cost‐effectiveness of bevacizumab using a Markov model based on the GOG‐240 study. The total cost of bevacizumab plus chemotherapy was about 13.2 times that of chemotherapy alone (USD 79,844 versus USD 6053), and the incremental cost‐effectiveness ratio (ICER) was USD 295,164 per quality‐adjusted life‐year (QALY) or USD 24,597 per quality‐adjusted life‐month (1 study, 452 participants; low‐certainty evidence). </p> </section> </section> <section id="CD013348-sec-0070"> <h4 class="title">Cediranib plus chemotherapy versus chemotherapy only</h4> <section id="CD013348-sec-0071"> <h5 class="title">Overall survival</h5> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> reported risk of death (HR 0.94, 95% CI 0.53 to 1.65; 1 study, 69 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0014" title="">Analysis 2.1</a><a href="./full#CD013348-tbl-0002">summary of findings Table 2</a>); median OS was 13.6 months in the cediranib group (mortality rate 25/34 participants) and 14.8 months in the placebo group (mortality rate 27/35 participants). The effect of cediranib on overall survival might depend on disease site. </p> <p> <ul id="CD013348-list-0021"> <li> <p>The 95% CI for the extra‐pelvic metastases only subgroup (N = 21) showed greater benefit compared to the 95% CI for those with local relapse (N = 48) but showed no effects on age, histological subtype, length of disease‐free survival, number of previous treatments, or performance status (details of HR and CI were not provided). </p> </li> <li> <p>The 95% CIs for both the squamous subgroup (N = 47) and the non‐squamous subgroup (N = 22) showed appreciable benefit and harm (details of HR and CI were not provided). </p> </li> </ul> </p> </section> <section id="CD013348-sec-0072"> <h5 class="title">Specific adverse events</h5> <section id="CD013348-sec-0073"> <h6 class="title">Gastrointestinal perforations or fistulae</h6> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> reported gastrointestinal perforations or fistulae in 1 of 32 participants receiving cediranib plus chemotherapy and in 0 of 35 participants receiving placebo plus chemotherapy (RR 3.27, 95% CI 0.14 to 77.57; 1 study, 67 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0015" title="">Analysis 2.2</a>). </p> </section> <section id="CD013348-sec-0074"> <h6 class="title">Haemorrhage</h6> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> reported serious haemorrhage in 2 of 32 participants receiving cediranib plus chemotherapy and in 0 of 35 participants receiving placebo plus chemotherapy (RR 5.45, 95% CI 0.27 to 109.49; 1 study, 67 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD013348-sec-0075"> <h6 class="title">Thromboembolic events</h6> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> reported serious thromboembolic events in 1 of 28 participants receiving cediranib plus chemotherapy and in 0 of 32 participants receiving placebo plus chemotherapy (RR 3.41, 95% CI 0.14 to 80.59; 1 study, 60 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0017" title="">Analysis 2.4</a>). </p> </section> <section id="CD013348-sec-0076"> <h6 class="title">Hypertension</h6> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> reported serious hypertension in 0 of 32 participants receiving cediranib plus chemotherapy and in 1 of 35 participants receiving placebo plus chemotherapy (RR 0.36, 95% CI 0.02 to 8.62; 1 study, 67 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0018" title="">Analysis 2.5</a>). </p> </section> </section> <section id="CD013348-sec-0077"> <h5 class="title">Progression‐free survival</h5> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> reported risk of disease progression (HR 0.58, 95% CI 0.33 to 1.03; 1 study, 69 participants; <a href="./references#CD013348-fig-0019" title="">Analysis 2.6</a>); median PFS was 8.1 months in the cediranib group (morbidity rate 26/34 participants) and 6.7 months in the placebo group (morbidity rate 29/35 participants). </p> </section> <section id="CD013348-sec-0078"> <h5 class="title">Quality of life</h5> <p>In <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, participants were assessed with the European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐C30 questionnaire (<a href="./references#CD013348-bbs2-0023" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365-76.">Aaronson 1993</a>). There may or may not be a difference in QoL (median area under the curve values, AUC values from analysis of EORTC QLQ‐C30 by time spent) at 13 time points between cediranib (median AUC ‐5.4, 95% CI ‐13.1 to ‐1.0) and placebo (median AUC ‐11.1, 95% CI ‐20.8 to ‐7.4). QoL associated with diarrhoea was probably worse in women with cediranib (median AUC difference 18, 95% CI 5 to 37). </p> </section> <section id="CD013348-sec-0079"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> reported total adverse events in 32 of 32 participants receiving cediranib plus chemotherapy and in 35 of 35 participants receiving placebo plus chemotherapy (RR 1.00, 95% CI 0.94 to 1.06; 1 study, 67 participants; <a href="./references#CD013348-fig-0021" title="">Analysis 2.8</a>) and serious adverse events in 19 of 32 participants receiving cediranib plus chemotherapy and in 18 of 35 participants receiving placebo plus chemotherapy (RR 1.15, 95% CI 0.75 to 1.78; 1 study, 67 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0022" title="">Analysis 2.9</a>). </p> </section> <section id="CD013348-sec-0080"> <h5 class="title">Economic evaluation</h5> <p>This was not measured.</p> </section> </section> <section id="CD013348-sec-0081"> <h4 class="title">Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only </h4> <section id="CD013348-sec-0082"> <h5 class="title">Overall survival</h5> <p><a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> reported risk of death (HR 0.90, 95% CI 0.51 to 1.60; 1 study, 52 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0023" title="">Analysis 3.1</a>; <a href="./full#CD013348-tbl-0003">summary of findings Table 3</a>); median OS was 14.7 months in the apatinib group (mortality rate 11/28 participants) and 12.8 months in the control group (mortality rate 16/24 participants). </p> </section> <section id="CD013348-sec-0083"> <h5 class="title">Summary of adverse events</h5> <p>Apatinib required dose reduction in three participants due to severe treatment‐associated toxicity, including hypertension and hand‐foot syndrome. Severe hypertension and hand‐foot syndrome were adequately relieved when the drug dose was reduced, or when participants were given symptomatic treatment to support medication adherence and apatinib tolerance. Apatinib did not significantly increase the incidence of neutropenia compared with control (75% versus 75%), nor the incidence of anaemia (75% versus 66.7%); diarrhoea (57.1% versus 41.6%); nausea and vomiting (57.1% versus 37.5%); fatigue (50% versus 25%); dysuria, urinary urgency, and urinary frequency (28.6% versus 25%); alopecia (18.6% versus 25%); thrombocytopenia (25% versus 16.7%); and liver toxicity (14.3% versus 12.5%). However, proteinuria (53.6% versus 16.7%), hand‐foot syndrome (50% versus 16.7%), mucositis (46.4% versus 12.5%), and hypertension (42.8% versus 8.3%) at all severities were more common in the apatinib group than in the control group. </p> </section> <section id="CD013348-sec-0084"> <h5 class="title">Specific adverse events</h5> <section id="CD013348-sec-0085"> <h6 class="title">Gastrointestinal perforations or fistulae</h6> <p>This was not reported.</p> </section> <section id="CD013348-sec-0086"> <h6 class="title">Haemorrhage</h6> <p>This was not reported.</p> </section> <section id="CD013348-sec-0087"> <h6 class="title">Thromboembolic events</h6> <p>This was not reported.</p> </section> <section id="CD013348-sec-0088"> <h6 class="title">Hypertension</h6> <p><a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> reported a higher incidence of hypertension in 12 of 28 participants receiving apatinib plus chemotherapy or chemotherapy/brachytherapy compared to 2 of 24 participants receiving chemotherapy or chemotherapy/brachytherapy (RR 5.14, 95% CI 1.28 to 20.73; 1 study, 52 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0024" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD013348-sec-0089"> <h5 class="title">Progression‐free survival</h5> <p>In <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, treatment with apatinib plus chemotherapy or chemotherapy/brachytherapy resulted in lower risk of disease progression compared to chemotherapy or chemotherapy/brachytherapy alone (HR 0.44, 95% CI 0.25 to 0.78; 1 study, 52 participants; <a href="./references#CD013348-fig-0025" title="">Analysis 3.3</a>). <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> reported median PFS as 10.1 months in the apatinib group and 6.4 months in the control group. </p> </section> <section id="CD013348-sec-0090"> <h5 class="title">Quality of life</h5> <p>This was not measured.</p> </section> <section id="CD013348-sec-0091"> <h5 class="title">Economic evaluation</h5> <p>This was not measured.</p> </section> </section> <section id="CD013348-sec-0092"> <h4 class="title">Pazopanib plus lapatinib versus lapatinib only</h4> <section id="CD013348-sec-0093"> <h5 class="title">Overall survival</h5> <p>In <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, treatment with pazopanib plus lapatinib probably resulted in higher risk of death compared to treatment with lapatinib alone (HR 2.71, 95% CI 1.16 to 6.31; 2 arms from 1 study, 117 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0026" title="">Analysis 4.1</a>; <a href="./full#CD013348-tbl-0004">summary of findings Table 4</a>). <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported median OS in the pazopanib plus lapatinib group as 25.7 weeks (mortality rate 14/59 participants) and in the lapatinib group as 35.0 weeks (mortality rate 10/58 participants). </p> </section> <section id="CD013348-sec-0094"> <h5 class="title">Specific adverse events</h5> <section id="CD013348-sec-0095"> <h6 class="title">Gastrointestinal perforations or fistulae</h6> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported gastrointestinal perforations or fistulae in 2 of 76 participants receiving pazopanib plus lapatinib and in 1 of 76 participants receiving lapatinib alone (RR 2.00, 95% CI 0.19 to 21.59; 2 arms from 1 study, 152 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0027" title="">Analysis 4.2</a>). </p> </section> <section id="CD013348-sec-0096"> <h6 class="title">Haemorrhage</h6> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported haemorrhage in 10 of 76 (at least 10) participants receiving pazopanib plus lapatinib and in 5 of 76 (at least five) participants receiving lapatinib alone (RR 2.00, 95% CI 0.72 to 5.58; 2 arms from 1 study, 152 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0028" title="">Analysis 4.3</a>). </p> </section> <section id="CD013348-sec-0097"> <h6 class="title">Thromboembolic events</h6> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported thromboembolic events in 1 of 76 participants receiving pazopanib plus lapatinib and in 0 of 76 participants receiving lapatinib alone (RR 3.00, 95% CI 0.12 to 72.50; 2 arms from 1 study, 152 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0029" title="">Analysis 4.4</a>). </p> </section> <section id="CD013348-sec-0098"> <h6 class="title">Hypertension</h6> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported a higher incidence of hypertension in 24 of 76 participants receiving pazopanib plus lapatinib compared to 2 of 76 participants receiving lapatinib alone (RR 12.00, 95% CI 2.94 to 49.01; 2 arms from 1 study, 152 participants; moderate‐certainty evidence; <a href="./references#CD013348-fig-0030" title="">Analysis 4.5</a>). </p> </section> </section> <section id="CD013348-sec-0099"> <h5 class="title">Progression‐free survival</h5> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported risk of disease progression (HR 1.05, 95% CI 0.59 to 1.86; 2 arms from 1 study, 117 participants; <a href="./references#CD013348-fig-0031" title="">Analysis 4.6</a>); median PFS was 12.6 months in the pazopanib plus lapatinib group (morbidity rate 20/59 participants) and 12.6 months in the lapatinib alone group (morbidity rate 28/58 participants). </p> </section> <section id="CD013348-sec-0100"> <h5 class="title">Quality of life</h5> <p>This was not measured.</p> </section> <section id="CD013348-sec-0101"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported total adverse events in 72 of 76 participants receiving pazopanib plus lapatinib and in 71 of 76 participants receiving lapatinib (RR 1.01, 95% CI 0.94 to 1.10; 2 arms from 1 study, 152 participants; <a href="./references#CD013348-fig-0032" title="">Analysis 4.7</a>) and serious adverse events in 32 of 76 participants receiving pazopanib plus lapatinib and in 22 of 76 participants receiving lapatinib alone (RR 1.45, 95% CI 0.94 to 2.26; 2 arms from 1 study, 152 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0033" title="">Analysis 4.8</a>). </p> </section> <section id="CD013348-sec-0102"> <h5 class="title">Economic evaluation</h5> <p>This was not measured.</p> </section> </section> <section id="CD013348-sec-0103"> <h4 class="title">Pazopanib versus lapatinib</h4> <section id="CD013348-sec-0104"> <h5 class="title">Overall survival</h5> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported risk of death (HR 0.96, 95% CI 0.67 to 1.38; 2 arms from 1 study, 152 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0034" title="">Analysis 5.1</a>; <a href="./full#CD013348-tbl-0005">summary of findings Table 5</a>); median OS was 49.7 weeks in the pazopanib group (mortality rate 56/74 participants) and 44.1 weeks in the lapatinib group (mortality rate 62/78 participants). </p> </section> <section id="CD013348-sec-0105"> <h5 class="title">Specific adverse events</h5> <section id="CD013348-sec-0106"> <h6 class="title">Gastrointestinal perforations or fistulae</h6> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported gastrointestinal perforations or fistulae in 1 of 74 participants receiving pazopanib monotherapy and in 1 of 76 participants receiving lapatinib monotherapy (RR 1.03, 95% CI 0.07 to 16.12; 2 arms from 1 study, 150 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0035" title="">Analysis 5.2</a>). </p> </section> <section id="CD013348-sec-0107"> <h6 class="title">Haemorrhage</h6> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported haemorrhage in 5 of 74 (at least five) participants receiving pazopanib monotherapy and in 5 of 76 (at least five) participants receiving lapatinib monotherapy (RR 1.03, 95% CI 0.31 to 3.40; 2 arms from 1 study, 150 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0036" title="">Analysis 5.3</a>). </p> </section> <section id="CD013348-sec-0108"> <h6 class="title">Thromboembolic events</h6> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported thromboembolic events in 1 of 74 participants receiving pazopanib monotherapy and in 0 of 76 participants receiving lapatinib monotherapy (RR 3.08, 95% CI 0.13 to 74.42; 2 arms from 1 study, 150 participants; very low‐certainty evidence; <a href="./references#CD013348-fig-0037" title="">Analysis 5.4</a>). </p> </section> <section id="CD013348-sec-0109"> <h6 class="title">Hypertension</h6> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported a higher incidence of hypertension in 23 of 74 participants receiving pazopanib monotherapy compared to 2 of 76 participants receiving lapatinib monotherapy (RR 11.81, 95% CI 2.89 to 48.33; 2 arms from 1 study, 150 participants; moderate‐certainty evidence; <a href="./references#CD013348-fig-0038" title="">Analysis 5.5</a>). </p> </section> </section> <section id="CD013348-sec-0110"> <h5 class="title">Progression‐free survival</h5> <p>In <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, treatment with pazopanib monotherapy probably resulted in lower risk of disease progression compared to lapatinib monotherapy (HR 0.66, 95% CI 0.45 to 0.97; 2 arms from 1 study, 152 participants; <a href="./references#CD013348-fig-0039" title="">Analysis 5.6</a>); <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported median PFS as 18.1 weeks in the pazopanib group (morbidity rate 46/74 participants) and as 17.1 weeks in the lapatinib group (morbidity rate 59/78 participants). </p> </section> <section id="CD013348-sec-0111"> <h5 class="title">Quality of life</h5> <p>This was not measured.</p> </section> <section id="CD013348-sec-0112"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> reported total adverse events in 72 of 74 participants receiving pazopanib monotherapy and in 71 of 76 participants receiving lapatinib monotherapy (RR 1.04, 95% CI 0.97 to 1.12; 2 arms from 1 study, 150 participants; <a href="./references#CD013348-fig-0040" title="">Analysis 5.7</a>) and serious adverse events in 28 of 74 participants receiving pazopanib monotherapy and in 22 of 76 participants receiving lapatinib monotherapy (RR 1.31, 95% CI 0.83 to 2.07; 2 arms from 1 study, 150 participants; low‐certainty evidence; <a href="./references#CD013348-fig-0041" title="">Analysis 5.8</a>). </p> </section> <section id="CD013348-sec-0113"> <h5 class="title">Economic evaluation</h5> <p>This was not measured.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013348-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013348-sec-0114"></div> <section id="CD013348-sec-0115"> <h3 class="title" id="CD013348-sec-0115">Summary of main results</h3> <p>The review authors identified four studies with a total of 808 participants. <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> and <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a> were funded by government agencies. <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> and <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a> were funded by manufacturers. </p> <p>One study included 452 women and compared bevacizumab plus chemotherapy versus chemotherapy alone (<a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>). Bevacizumab improved overall survival (OS) (low‐certainty evidence); however, it increased specific adverse events including gastrointestinal perforations or fistulae (moderate‐certainty evidence), serious haemorrhage (low‐certainty evidence), serious thromboembolic events (moderate‐certainty evidence), and hypertension (moderate‐certainty evidence); it also increased serious adverse events (moderate‐certainty evidence) and costs (low‐certainty evidence). </p> <p>A second study included 69 women and compared cediranib plus chemotherapy versus placebo plus chemotherapy (<a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>). Cediranib made no difference in OS (low‐certainty evidence) nor in specific adverse events including gastrointestinal perforations or fistulae (very low‐certainty evidence), serious haemorrhage (very low quality of evidence), serious thromboembolic events (very low‐certainty evidence), and serious hypertension (very low‐certainty evidence); it also made no difference in serious adverse events (low‐certainty evidence). </p> <p>A third study included 59 women and compared apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy alone (<a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>). Apatinib made no difference in OS (low‐certainty evidence) but increased hypertension (low‐certainty evidence). </p> <p>A fourth trial included 228 women (<a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>). This study compared (1) pazopanib plus lapatinib versus lapatinib alone, and (2) pazopanib versus lapatinib. </p> <p> <ul id="CD013348-list-0022"> <li> <p>Pazopanib plus lapatinib versus lapatinib alone: pazopanib plus lapatinib reduced OS (low‐certainty evidence); made no difference in some specific adverse events including gastrointestinal perforations or fistulae (very low‐certainty evidence), haemorrhage (very low‐certainty evidence), thromboembolic events (very low‐certainty evidence), and increased hypertension (moderate‐certainty evidence); and made no difference in serious adverse events (low‐certainty evidence). </p> </li> <li> <p>Pazopanib versus lapatinib: pazopanib made no difference in OS (low‐certainty evidence); made no difference in some specific adverse events including gastrointestinal perforations or fistulae (very low‐certainty evidence), haemorrhage (very low‐certainty evidence), thromboembolic events (very low‐certainty evidence), and increased hypertension (moderate‐certainty evidence); and made no difference in serious adverse events (low‐certainty evidence). </p> </li> </ul> </p> <p>The review authors found two completed studies with a total of 115 women and added these to <a href="./references#CD013348-bbs1-0003" title="">Studies awaiting classification</a>. One study included 75 women and compared bevacizumab plus chemoradiotherapy versus chemoradiotherapy alone for women with advanced cervical adenocarcinoma and did not address OS (<a href="./references#CD013348-bbs2-0013" title="XieZ , WanY . Efficacy of bevacizumab combined with cisplatin chemotherapy and definitive radiotherapy in treatment of advanced cervical adenocarcinoma (Chinese). Journal of Practical Oncology2016;31(5):455-8. ">Xie 2016</a>). A second study included 40 women, compared apatinib plus chemoradiotherapy versus chemoradiotherapy alone for women with FIGO (International Federation of Obstetrics and Gynaecology) stage IIB to IV cervical cancer, and addressed OS (<a href="./references#CD013348-bbs2-0012" title="RaoL , XiaC , XieZ , ZhangT , CuiC , ChenJ , et al. Clinical efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of advanced cervical cancer (Chinese). Anti-tumor Pharmacy2018;8(5):767-71. ">Rao 2018</a>). Both studies were not registered online (<a href="./references#CD013348-bbs2-0012" title="RaoL , XiaC , XieZ , ZhangT , CuiC , ChenJ , et al. Clinical efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of advanced cervical cancer (Chinese). Anti-tumor Pharmacy2018;8(5):767-71. ">Rao 2018</a>; <a href="./references#CD013348-bbs2-0013" title="XieZ , WanY . Efficacy of bevacizumab combined with cisplatin chemotherapy and definitive radiotherapy in treatment of advanced cervical adenocarcinoma (Chinese). Journal of Practical Oncology2016;31(5):455-8. ">Xie 2016</a>); although we contacted their principal investigators, no additional data were provided. </p> <p>The review authors also identified nine ongoing studies (expected recruitment 854 participants) for three tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor (VEGF) receptor (VEGF‐R) (apatinib, anlotinib, nintedanib). These studies have not reported any outcomes to date (<a href="./references#CD013348-bbs1-0004" title="">Ongoing studies</a>). </p> </section> <section id="CD013348-sec-0116"> <h3 class="title" id="CD013348-sec-0116">Overall completeness and applicability of evidence</h3> <p>The four included studies were insufficient to address all of the objectives of this review. Types of interventions were limited, including bevacizumab plus chemotherapy, cediranib plus chemotherapy, apatinib plus chemotherapy or chemotherapy/brachytherapy, pazopanib plus lapatinib, and pazopanib monotherapy. Overall completeness and applicability of evidence were low, as each comparison included only one study, and most studies were small. </p> <p>Factors such as disease spread, histological type, and risk category should be considered in the applicability of main results. Tumour biology may be different between pelvic site and extra‐pelvic metastasis, between measurable and unmeasurable, between squamous and non‐squamous, and between low risk and medium/high risk. The benefit of bevacizumab plus chemotherapy appears to be greater in women untreated with pelvic disease, cancers of squamous histological type, and medium/high risk. The effect of cediranib plus chemotherapy appears to be invalid in untreated women, especially for those with extra‐pelvic disease. </p> <p>Apatinib may make little to no difference in survival among untreated women; however, <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> mixed two types of interventions: apatinib plus chemotherapy in women with recurrent disease, and apatinib plus chemotherapy/brachytherapy in women with stage IVB disease. No independent survival results were provided for chemotherapy or chemotherapy/brachytherapy. </p> <p>Pazopanib plus lapatinib reduced OS, and data do not support this treatment for women who have received prior anti‐cancer therapies. Pazopanib monotherapy may not be better (except for progression‐free survival) than lapatinib monotherapy for women who have received prior anti‐cancer therapies. </p> <p>These studies reported substantial discontinuation of treatment or toxicity (participants did not complete the intervention). Regardless of the intention‐to‐treat population, 95%, 99%, and 94% of participants discontinued the intervention in <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, and <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, respectively. Discontinuation implied that most women needed additional salvage therapy or supportive care. </p> <p>Bevacizumab improved OS by 3.5 months (versus median 13.3 months) with a higher incidence (52%, 114/220 versus 36%, 79/219) of serious adverse events and higher incremental costs in the bevacizumab plus chemotherapy groups. Women with a high preference for survival prolongation and with limited aversion to serious adverse events who do not consider bevacizumab therapy a burden may opt to use bevacizumab; others may not. </p> </section> <section id="CD013348-sec-0117"> <h3 class="title" id="CD013348-sec-0117">Quality of the evidence</h3> <p>Risk of selection bias was low in <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, and <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, as participants were randomly assigned by validated randomisation systems. Risk of selection bias was unclear in <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, as information about random sequence generation or allocation concealment was not available. Risk of performance and detection bias was low in <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, as participants, investigators, and outcomes assessors were blinded. Risk of performance and detection bias was high for subjective outcomes (i.e. progression‐free survival, quality of life) in <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, and <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a> as 'open‐label' but was low for objective outcomes (i.e. OS, adverse events, economic evaluation). Risk of attrition was low in all four studies. Risk of reporting bias was low in <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>, and <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, as outcomes in the protocols were the same in these publications. Risk of reporting bias was high in <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a>, as study registration occurred later than study completion. Risk of other bias was high in <a href="./references#CD013348-bbs2-0001" title="ChiCTR1900024143. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage. Chinese Clinical Trial Registry (accessed 2 December 2019). GuoQ , SunY , KongE , RaoL , ChenJ , WuQ , et al. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine2020;99(11):e19372. ">Guo 2020</a> and <a href="./references#CD013348-bbs2-0002" title="2006-000236-27. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. EU Clinical Trials Register (accessed 2 December 2019). MonkB , MasL , Zarba, JJ, OakninA , TarpinC , TermrungruanglertW , et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology2009;27(15 Suppl):5520. MonkBJ , Mas LopezL , ZarbaJJ , OakninA , TarpinC , TermrungruanglertW , et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2010;28(22):3562-9. MonkBJ , PanditeLN . Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology2011;29(36):4845. NCT00430781. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). VEG105281. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease. GSK Clinical Study Register (accessed 2 December 2019). ">Monk 2010</a>, as these studies were supported and sponsored by the manufacturer. Risk of other bias was unclear in <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>, as economic evaluation was not a planned analysis in the study protocol. </p> <p>The level of certainty of evidence for bevacizumab plus chemotherapy compared to chemotherapy was low to moderate (<a href="./full#CD013348-tbl-0001">summary of findings Table 1</a>). We downgraded all outcomes by one for serious heterogeneity, as outcomes might be different for different subgroups in the only included study if the sample were larger. In addition, we downgraded 'OS and serious haemorrhage' by one for serious imprecision, as optimal information size was not met; we downgraded 'economic evaluation' by one for serious risk of bias, as this was not a planned analysis in the study protocol. </p> <p>The level of certainty of evidence for 'cediranib plus chemotherapy compared to placebo plus chemotherapy' was low to very low (<a href="./full#CD013348-tbl-0002">summary of findings Table 2</a>). We downgraded all outcomes by one for serious heterogeneity, as outcomes might be different for different subgroups in the only included study and with a large sample. In addition, we downgraded 'OS' by one for serious imprecision, as optimal information size was not met; we downgraded 'gastrointestinal perforations or fistulae, serious haemorrhage, serious thromboembolic events, and serious hypertension' by two for very serious imprecision, as there were few events and the confidence interval included appreciable benefit and harm; we downgraded 'serious adverse events' by one for serious imprecision, as optimal information size was not met. </p> <p>The level of certainty of evidence for 'apatinib plus chemotherapy or chemotherapy/brachytherapy compared to chemotherapy or chemotherapy/brachytherapy' was low (<a href="./full#CD013348-tbl-0003">summary of findings Table 3</a>). We downgraded all outcomes by one for serious risk of bias, as the only included study was funded by the drug manufacturer. In addition, we downgraded 'OS' by one for serious imprecision, as optimal information size was not met; we downgraded 'hypertension' by one for serious risk of bias, as trial registration occurred later than study completion. </p> <p>The level of certainty of evidence for 'pazopanib plus lapatinib compared to lapatinib' was moderate to very low (<a href="./full#CD013348-tbl-0004">summary of findings Table 4</a>). We downgraded all outcomes by one for serious risk of bias, as the only included study was funded by the drug manufacturer and this may have contributed to bias in the final results. In addition, we downgraded 'OS' by one for serious imprecision, as optimal information size was not met; we downgraded 'gastrointestinal perforations or fistulae, haemorrhage, and thromboembolic events' by two for very serious imprecision, as there were few events and the confidence interval included appreciable benefit and harm; we downgraded 'serious adverse events' by one for serious imprecision, as optimal information size was not met. </p> <p>The level of certainty of evidence for 'pazopanib compared to lapatinib' was moderate to very low (<a href="./full#CD013348-tbl-0005">summary of findings Table 5</a>). We downgraded all outcomes by one for serious risk of bias, as the only included study was funded by the drug manufacturer and this may have biased the final outcomes. In addition, we downgraded 'OS' by one for serious imprecision, as optimal information size was not met; we downgraded 'gastrointestinal perforations or fistulae, haemorrhage, and thromboembolic events' by two for very serious imprecision, as there were few events and the confidence interval included appreciable benefit and harm; we downgraded 'serious adverse events' by one for serious imprecision, as optimal information size was not met. </p> </section> <section id="CD013348-sec-0118"> <h3 class="title" id="CD013348-sec-0118">Potential biases in the review process</h3> <p>To prevent potential biases in the review process, we performed a comprehensive search, including a thorough search of multiple databases, online registers of clinical trials, and conference proceedings, with assistance from the Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group. Three review authors independently performed all relevant processes (search, data collection, and analysis). We were unable to assess publication bias, as the review included only four studies. </p> <p>Two awaiting classification studies addressed the effects of agents (apatinib or bevacizumab) plus chemoradiotherapy. Even with data, the two small studies (115 total participants) may not be able to answer the main question of this review. </p> <p>The effects of other agents (apatinib, anlotinib, or nintedanib) plus chemotherapy are being assessed in seven ongoing studies. </p> </section> <section id="CD013348-sec-0119"> <h3 class="title" id="CD013348-sec-0119">Agreements and disagreements with other studies or reviews</h3> <p>The results of this Cochrane Review on the efficacy of anti‐VEGF antibody (bevacizumab) were consistent with those of other published systematic reviews (<a href="./references#CD013348-bbs2-0101" title="RosenVM , GuerraI , McCormackM , Nogueira-RodriguesA , SasseA , MunkVC , et al. Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. International Journal of Gynecological Cancer2017;27(6):1237-46.">Rosen 2017</a>; <a href="./references#CD013348-bbs2-0127" title="ZagouriF , SergentanisTN , ChrysikosD , FilipitsM , BartschR . Molecularly targeted therapies in cervical cancer. A systematic review. Gynecologic Oncology2012;126(2):291-303.">Zagouri 2012</a>), as well as a multitude of narrative reviews (<a href="./references#CD013348-bbs2-0024" title="AlldredgeJK , TewariKS . Clinical trials of antiangiogenesis therapy in recurrent/persistent and metastatic cervical cancer. Oncologist2016;21(5):576-85.">Alldredge 2016</a>; <a href="./references#CD013348-bbs2-0049" title="EskanderRN , TewariKS . Targeting angiogenesis in advanced cervical cancer. Therapeutic Advances in Medical Oncology2014;6(6):280-92.">Eskander 2014</a>; <a href="./references#CD013348-bbs2-0055" title="GadducciA , LanfrediniN , SergiampietriC . Antiangiogenic agents in gynecological cancer: state of art and perspectives of clinical research. Critical Reviews in Oncology/Hematology2015;96(1):113-28.">Gadducci 2015</a>; <a href="./references#CD013348-bbs2-0069" title="JaysonGC , KerbelR , EllisLM , HarrisAL . Antiangiogenic therapy in oncology: current status and future directions. Lancet2016;388(10043):518-29.">Jayson 2016</a>; <a href="./references#CD013348-bbs2-0075" title="KrillLS , TewariKS . Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer. Clinical Therapeutics2015;37(1):9-19.">Krill 2015</a>; <a href="./references#CD013348-bbs2-0079" title="LuveroD , PlottiF , LopezS , ScalettaG , CapriglioneS , MonteraR , et al. Antiangiogenics and immunotherapies in cervical cancer: an update and future's view. Medical Oncology2017;34(6):115.">Luvero 2017</a>; <a href="./references#CD013348-bbs2-0085" title="MinionLE , TewariKS . The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Review of Anticancer Therapy2017;17(3):191-8.">Minion 2017</a>; <a href="./references#CD013348-bbs2-0098" title="PfaendlerKS , LiuMC , TewariKS . Bevacizumab in cervical cancer: 5 years after. Cancer Journal2018;24(4):187-92.">Pfaendler 2018</a>; <a href="./references#CD013348-bbs2-0117" title="TomaoF , PapaA , RossiL , ZaccarelliE , CarusoD , ZorattoF , et al. Angiogenesis and antiangiogenic agents in cervical cancer. OncoTargets and Therapy2014;7:2237-48.">Tomao 2014</a>; <a href="./references#CD013348-bbs2-0123" title="WeiXW , ZhangZR , WeiYQ . Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment. Expert Opinion on Investigational Drugs2013;22(9):1181-92.">Wei 2013</a>). <a href="./references#CD013348-bbs2-0127" title="ZagouriF , SergentanisTN , ChrysikosD , FilipitsM , BartschR . Molecularly targeted therapies in cervical cancer. A systematic review. Gynecologic Oncology2012;126(2):291-303.">Zagouri 2012</a> was a systematic review that included 23 phase 1 and 2 trials and seven observational studies to narrate molecular targeted therapy for cervical cancer (not limited to persistent, recurrent, or metastatic disease). These molecular targeted agents included anti‐VEGF antibody (bevacizumab), TKIs of VEGF‐R, TKIs of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), mammalian target of rapamycin inhibitors, cyclo‐oxygenase‐2 inhibitors, and histone deacetylase inhibitors, among others. No phase 3 trials were found. The results for bevacizumab from five non‐randomised studies were promising. <a href="./references#CD013348-bbs2-0101" title="RosenVM , GuerraI , McCormackM , Nogueira-RodriguesA , SasseA , MunkVC , et al. Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. International Journal of Gynecological Cancer2017;27(6):1237-46.">Rosen 2017</a> was a systematic review and network meta‐analysis that included five randomised controlled trials (RCTs) (<a href="./references#CD013348-bbs2-0074" title="KitagawaR , KatsumataN , ShibataT , KamuraT , KasamatsuT , NakanishiT , et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. Journal of Clinical Oncology2015;33(19):2129-35.">Kitagawa 2015</a>; <a href="./references#CD013348-bbs2-0078" title="Long HJ 3rd, BundyBN , Grendys EC Jr, BendaJA , McMeekinDS , SoroskyJ , et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2005;23(21):4626-33.">Long 2005</a>; <a href="./references#CD013348-bbs2-0087" title="MonkBJ , SillMW , McMekinS , CohnDE , RamodettaLM , BoardmanCH , et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynaecological Oncology Group study. Journal of Clinical Oncology2009;27(28):4649-55.">Monk 2009b</a>; <a href="./references#CD013348-bbs2-0003" title="2009-011542-25. CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. EU Clinical Trials Register (accessed 2 December 2019). ISRCTN23516549. CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. ISCRTN Registry (accessed 2 December 2019). NCT01229930. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. ClinicalTrials.gov (accessed 2 December 2019). SymondsRP , GourleyC , DavidsonS , CartyK , McCartneyE , RaiD , et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology2015;16(15):1515-24. ZhouC , TaylorS , TugwoodJ , SimpsonK , JaysonGC , SymondsP , et al. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology2019;85(8):1781-9. ">Symonds 2015</a>; <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>); this review showed that bevacizumab plus chemotherapy (paclitaxel/topotecan and paclitaxel/cisplatin) was likely to prolong OS over other non‐bevacizumab chemotherapy regimens, which were not included in <a href="./references#CD013348-bbs2-0004" title="2010-023525-38. Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix [Ensayo en fase III aleatorizado de cisplatino mas paclitaxel con y sin bevacizumab frente al doblete sin platino, topotecan mas paclitaxel, con y sin bevacizumab, en carcinoma de cervix en estadio ivb, recurrente o persistente (Spanish)]. EU Clinical Trials Register (accessed 2 December 2019). ChaseD , HuangHQ , MonkBJ , RamondettaLM , PensonRT , GilK , et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer2020;pii: ijgc-2019-000869:Epub ahead of print. EskanderRN , JavaJ , MonkBJ , TewariKS . Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):28. MinionL , TewariKS , ChanJK , PensonRT , CohnDE , MonkBJ . A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. International Journal of Gynecological Cancer2013;23(8 Suppl 1):241. MinionLE , BaiJ , MonkBJ , Robin KellerL , RamezEN , FordeGK , et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology2015;137(3):490-6. NCT00803062. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer. ClinicalTrials.gov (accessed 2 December 2019). PensonRT , HuangH , TewariKS , LongHJ , RamondettaLM , LandrumLM , et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study. European Journal of Cancer2013;49(Suppl 3):S18. PensonRT , HuangHQ , WenzelLB , MonkBJ , StockmanS , Long HJ 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology2015;16(3):301-11. TewariKS , SillM , LongHJ , RamondettaLM , LandrumLM , OakninA , et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology2013;31(18 Suppl):3. TewariKS , SillM , MonkBJ , LongHJ , PensonRT , HuangH , et al. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study. Gynecologic Oncology2014;133(Suppl 1):59-60. TewariKS , SillMW , Long HJ 3rd, PensonRT , HuangH , RamondettaLM , et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine2014;370(8):734-43. TewariKS , SillMW , MonkBJ , PensonRT , Long HJ 3rd, PovedaA , et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research2015;21(24):5480-7. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet2017;390(10103):1654-63. TewariKS , SillMW , PensonRT , HuangH , RamondettaLM , LandrumLM , et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study. Annals of Oncology2014;25(5 Suppl):LBA26. WaggonerSE , JavaJ , MonkBJ , MichaelH , PensonRT , LeitaoMM , et al. Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology2015;137(Suppl 1):143-4. ">Tewari 2014</a>. Our review provides the most recent information from RCTs about TKIs of VEGF‐R. This review aimed to provide evidence from multiple comparisons to evaluate the effectiveness and safety of different VEGF targeting agents alone or in the adjuvant setting for treatment of persistent, recurrent, or metastatic cervical cancer. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013348-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-FIG-01" target="_blank"><b></b></a></p> </div><img alt="FIGO stage 2018 (with correction Bhatla 2018; Bhatla 2019)." data-id="CD013348-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-01.jpg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-FIG-01.jpg" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>FIGO stage 2018 (with correction <a href="./references#CD013348-bbs2-0028" title="BhatlaN , AokiD , SharmaDN , SankaranarayananR . Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics2018;143(Suppl 2):22-36.">Bhatla 2018</a>; <a href="./references#CD013348-bbs2-0029" title="BhatlaN , BerekJS , CuelloFM , DennyLA , GrenmanS , KarunaratneK , et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology &amp; Obstetrics2019;145(1):129-35.">Bhatla 2019</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013348-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013348-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013348-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 1: Overall survival" data-id="CD013348-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 2: Specific adverse events: gastrointestinal perforations or fistulae" data-id="CD013348-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 2: Specific adverse events: gastrointestinal perforations or fistulae </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 3: Specific adverse events: serious haemorrhage" data-id="CD013348-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 3: Specific adverse events: serious haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 4: Specific adverse events: serious thromboembolic events" data-id="CD013348-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 4: Specific adverse events: serious thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 5: Specific adverse events: hypertension" data-id="CD013348-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 5: Specific adverse events: hypertension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 6: Progression‐free survival" data-id="CD013348-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 6: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0011"> <p> <div class="table" id="CD013348-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Quality of life</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tewari 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no difference in QoL (FACT‐Cx‐TOI scores) with or without bevacizumab (MD ‐1.2, 98.75% CI ‐4.1 to 1.7; participants = 390). </p> <p>There was no difference in neurotoxicity (FACT/GOG‐NTX scores) with or without bevacizumab (MD 0.23, 98.75% CI ‐1.19 to 1.64; participants = 390). </p> <p>There was no difference in pain (BPI) with or without bevacizumab (MD 0.5, 95% CI ‐0.14 to 1.14; participants = 390). </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 7: Quality of life </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0011">Navigate to figure in review</a></div> </div> <div class="figure" id="CD013348-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 8: Total adverse events" data-id="CD013348-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 8: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 9: Serious adverse events" data-id="CD013348-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Bevacizumab plus chemotherapy versus chemotherapy only, Outcome 9: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 1: Overall survival" data-id="CD013348-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 2: Specific adverse events: gastrointestinal perforations or fistulae" data-id="CD013348-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 2: Specific adverse events: gastrointestinal perforations or fistulae </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 3: Specific adverse events: serious haemorrhage" data-id="CD013348-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 3: Specific adverse events: serious haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 4: Specific adverse events: serious thromboembolic events" data-id="CD013348-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 4: Specific adverse events: serious thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 5: Specific adverse events: serious hypertension" data-id="CD013348-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 5: Specific adverse events: serious hypertension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 6: Progression‐free survival" data-id="CD013348-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 6: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0020"> <p> <div class="table" id="CD013348-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Quality of life</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Heading 1</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Symonds 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no difference in QoL (median AUC values, analysis of EORTC QLQ‐C30 by the time spent) at 13 time points between cediranib (median AUC ‐5.4, 95% CI ‐13.1 to ‐1.0) and placebo (median AUC ‐11.1, 95% CI ‐20.8 to ‐7.4). QoL associated with diarrhoea was worse in patients with cediranib (median AUC difference 18, 95% CI 5 to 37). </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 7: Quality of life </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD013348-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 8: Total adverse events" data-id="CD013348-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 8: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 9: Serious adverse events" data-id="CD013348-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Cediranib plus chemotherapy versus chemotherapy only, Outcome 9: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only, Outcome 1: Overall survival" data-id="CD013348-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only, Outcome 2: Specific adverse events: hypertension" data-id="CD013348-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only, Outcome 2: Specific adverse events: hypertension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only, Outcome 3: Progression‐free survival" data-id="CD013348-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only, Outcome 3: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 1: Overall survival" data-id="CD013348-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 2: Specific adverse events: gastrointestinal perforations or fistulae" data-id="CD013348-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 2: Specific adverse events: gastrointestinal perforations or fistulae </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 3: Specific adverse events: haemorrhage" data-id="CD013348-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 3: Specific adverse events: haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 4: Specific adverse events: thromboembolic events" data-id="CD013348-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 4: Specific adverse events: thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 5: Specific adverse events: hypertension" data-id="CD013348-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 5: Specific adverse events: hypertension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 6: Progression‐free survival" data-id="CD013348-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 6: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 7: Total adverse events" data-id="CD013348-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 7: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 8: Serious adverse events" data-id="CD013348-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Pazopanib plus lapatinib versus lapatinib only, Outcome 8: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pazopanib versus lapatinib, Outcome 1: Overall survival" data-id="CD013348-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Pazopanib versus lapatinib, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pazopanib versus lapatinib, Outcome 2: Specific adverse events: gastrointestinal perforations or fistulae" data-id="CD013348-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Pazopanib versus lapatinib, Outcome 2: Specific adverse events: gastrointestinal perforations or fistulae </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pazopanib versus lapatinib, Outcome 3: Specific adverse events: haemorrhage" data-id="CD013348-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Pazopanib versus lapatinib, Outcome 3: Specific adverse events: haemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pazopanib versus lapatinib, Outcome 4: Specific adverse events: thromboembolic events" data-id="CD013348-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Pazopanib versus lapatinib, Outcome 4: Specific adverse events: thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pazopanib versus lapatinib, Outcome 5: Specific adverse events: hypertension" data-id="CD013348-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Pazopanib versus lapatinib, Outcome 5: Specific adverse events: hypertension</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pazopanib versus lapatinib, Outcome 6: Progression‐free survival" data-id="CD013348-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Pazopanib versus lapatinib, Outcome 6: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pazopanib versus lapatinib, Outcome 7: Total adverse events" data-id="CD013348-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Pazopanib versus lapatinib, Outcome 7: Total adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013348-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/urn:x-wiley:14651858:media:CD013348:CD013348-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pazopanib versus lapatinib, Outcome 8: Serious adverse events" data-id="CD013348-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_t/tCD013348-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Pazopanib versus lapatinib, Outcome 8: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/media/CDSR/CD013348/image_n/nCD013348-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013348-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bevacizumab plus chemotherapy compared to chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bevacizumab plus chemotherapy compared to chemotherapy for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with persistent, recurrent, or metastatic cervical cancer </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> bevacizumab plus chemotherapy </p> <p><b>Comparison:</b> chemotherapy only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with the chemotherapy only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with bevacizumab plus chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>791 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>701 per 1000<br/>(621 to 774) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.77<br/>(0.62 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>452<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum follow‐up was longer than 50 months. Median overall survival in the bevacizumab groups was 16.8 months (mortality rate 170/227 participants). Median overall survival in the control groups was 13.3 months (mortality rate 178/225 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific</b> <b>adverse events: gastrointestinal perforations or fistulae</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1,000<br/>(11 to 608) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 18.00<br/>(2.42 to 133.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>440<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 18 women (a maximum of 23) had fistulae events (N = 18) or perforation events (N = 5) in the bevacizumab group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious haemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1,000<br/>(10 to 205) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.00<br/>(1.11 to 22.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>440<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious thromboembolic events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1,000<br/>(28 to 238) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.50<br/>(1.55 to 13.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>440<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: hypertension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1,000<br/>(92 to 678) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 13.75<br/>(5.07 to 37.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>440<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>361 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>519 per 1,000<br/>(418 to 646) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.44<br/>(1.16 to 1.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Economic evaluation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>452<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incremental cost‐effectiveness ratio (ICER) was USD 295,164 per quality‐adjusted life‐year (QALY), or USD 24,597 per quality‐adjusted life‐month </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious heterogeneity. Outcomes might be different in different subgroups in the only included study. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by one for serious risk of bias. This analysis was not planned in the study protocol. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bevacizumab plus chemotherapy compared to chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013348-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cediranib plus chemotherapy compared to placebo plus chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cediranib plus chemotherapy compared to placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with persistent, recurrent, or metastatic cervical cancer </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> cediranib plus chemotherapy </p> <p><b>Comparison:</b> placebo plus chemotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo plus chemotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cediranib plus chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>771 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000<br/>(543 to 912) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.94<br/>(0.53 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median follow‐up was 24.2 months. Median overall survival in the cediranib group was 13.6 months (mortality rate 25/34 participants). Median overall survival in the placebo group was 14.8 months (mortality rate 27/35 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: gastrointestinal perforations or fistulae</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.27<br/>(0.14 to 77.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious haemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.45<br/>(0.27 to 109.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious thromboembolic events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.41<br/>(0.14 to 80.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: serious</b> <b>hypertension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 246) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.36<br/>(0.02 to 8.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>514 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>591 per 1000<br/>(386 to 915) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.15<br/>(0.75 to 1.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic evaluation ‐ not measured</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious heterogeneity. Outcomes might be different in different subgroups in the only included study. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by two for very serious imprecision. There were few events and the confidence interval included appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cediranib plus chemotherapy compared to placebo plus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013348-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Apatinib plus chemotherapy or chemotherapy/brachytherapy compared to chemotherapy or chemotherapy/brachytherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Apatinib plus chemotherapy or chemotherapy/brachytherapy compared with chemotherapy or chemotherapy/brachytherapy for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with recurrent or FIGO stage IVB cervical cancer </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> apatinib plus chemotherapy or chemotherapy/brachytherapy </p> <p><b>Comparison:</b> chemotherapy or chemotherapy/brachytherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with <b>chemotherapy or chemotherapy/brachytherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with a<b>patinib</b> <b>plus chemotherapy or chemotherapy/brachytherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000<br/>(161 to 429) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.90<br/>(0.51 to 1.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median follow‐up was 14 months. Median overall survival in the apatinib group was 14.7 months (mortality rate 11/28 participants). Median overall survival in the control group was 12.8 months (mortality rate 16/24 participants) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: haemorrhage ‐ not reported</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: thromboembolic events ‐ not reported</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: hypertension</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>428 per 1000<br/>(107 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.14<br/>(1.28 to 20.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events ‐ not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic evaluation ‐ not measured</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; FIGO: International Federation of Obstetrics and Gynaecology; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious risk of bias. This single small study was funded by the drug manufacturer. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by one for serious risk of bias. Trial registration occurred later than trial completion. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Apatinib plus chemotherapy or chemotherapy/brachytherapy compared to chemotherapy or chemotherapy/brachytherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013348-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pazopanib plus lapatinib compared to lapatinib</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pazopanib plus lapatinib compared to lapatinib for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with persistent, recurrent, or metastatic cervical cancer </p> <p><b>Setting:</b> clinic </p> <p><b>Intervention:</b> pazopanib plus lapatinib </p> <p><b>Comparison:</b> lapatinib only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lapatinib only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with pazopanib plus lapatinib</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401 per 1000<br/>(197 to 697) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 2.71<br/>(1.16 to 6.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum follow‐up was longer than 40 weeks. Median overall survival in the pazopanib plus lapatinib group was 25.7 weeks (mortality rate 14/59 participants). Median overall survival in the lapatinib group was 35.0 weeks (mortality rate 10/58 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: gastrointestinal perforations or fistulae</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/>(3 to 284) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00<br/>(0.19 to 21.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: haemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1000<br/>(47 to 367) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00<br/>(0.72 to 5.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 10 women (maximum of 29) with 29 bleeding events were included in the pazopanib plus lapatinib group; at least 5 women (maximum of 11) with 11 bleeding events were included in the lapatinib group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: thromboembolic events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00<br/>(0.12 to 72.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: hypertension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>316 per 1000<br/>(77 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 12.00<br/>(2.94 to 49.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>289 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>420 per 1000<br/>(272 to 654) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.45<br/>(0.94 to 2.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A total of 5 women In the pazopanib plus lapatinib group had fatal adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic evaluation ‐ not measured</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious risk of bias. This single small study was funded by the drug manufacturer. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by two for very serious imprecision. There were few events and the confidence interval included appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pazopanib plus lapatinib compared to lapatinib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013348-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pazopanib compared to lapatinib</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pazopanib compared to lapatinib for persistent, recurrent, or metastatic cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with persistent, recurrent, or metastatic cervical cancer </p> <p><b>Setting:</b> clinic </p> <p><b>Intervention:</b> pazopanib only </p> <p><b>Comparison:</b> lapatinib only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects</b>* (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lapatinib only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with pazopanib only</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>795 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>781 per 1000<br/>(654 to 888) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.96<br/>(0.67 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum follow‐up was longer than 150 weeks. Median overall survival in the pazopanib group was 49.7 weeks (mortality rate 56/74 participants). Median overall survival in the lapatinib group was 44.1 weeks (mortality rate 62/78 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: gastrointestinal perforations or fistulae</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(1 to 212) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.07 to 16.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: haemorrhage</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(20 to 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.31 to 3.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 5 women (maximum of 13) in the pazopanib group had 13 bleeding events; at least 5 women (maximum of 11) in the lapatinib group had 11 bleeding events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: thromboembolic events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.08<br/>(0.13 to 74.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events: hypertension</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/>(76 to 1,000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 11.81<br/>(2.89 to 48.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>289 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>379 per 1000<br/>(240 to 599) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.31<br/>(0.83 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic evaluation ‐ not measured</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one for serious risk of bias. This single small study was funded by the drug manufacturer. </p> <p><sup>b</sup>Downgraded by one for serious imprecision. Optimal information size was not met. </p> <p><sup>c</sup>Downgraded by two for very serious imprecision. There were few events and the confidence interval included appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pazopanib compared to lapatinib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/full#CD013348-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013348-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bevacizumab plus chemotherapy versus chemotherapy only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Specific adverse events: gastrointestinal perforations or fistulae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Specific adverse events: serious haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Specific adverse events: serious thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Specific adverse events: hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bevacizumab plus chemotherapy versus chemotherapy only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013348-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cediranib plus chemotherapy versus chemotherapy only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Specific adverse events: gastrointestinal perforations or fistulae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Specific adverse events: serious haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Specific adverse events: serious thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Specific adverse events: serious hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cediranib plus chemotherapy versus chemotherapy only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013348-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Specific adverse events: hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Apatinib plus chemotherapy or chemotherapy/brachytherapy versus chemotherapy or chemotherapy/brachytherapy only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013348-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pazopanib plus lapatinib versus lapatinib only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Specific adverse events: gastrointestinal perforations or fistulae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Specific adverse events: haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Specific adverse events: thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Specific adverse events: hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pazopanib plus lapatinib versus lapatinib only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013348-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Pazopanib versus lapatinib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Specific adverse events: gastrointestinal perforations or fistulae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Specific adverse events: haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Specific adverse events: thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Specific adverse events: hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Pazopanib versus lapatinib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013348.pub2/references#CD013348-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013348.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013348-note-0025">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013348-note-0023">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013348-note-0024">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013348-note-0022">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013348-note-0020">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013348-note-0021">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013348-note-0015">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013348-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013348-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013348-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013348\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013348\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013348\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013348\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013348\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013348.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013348.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013348.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013348.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013348.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717375302"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013348.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717375306"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013348.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db65f1b8f9365',t:'MTc0MDcxNzM3NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 